| Year | Citation | Score | |||
|---|---|---|---|---|---|
| 2024 | Li J, Chin CR, Ying HY, Meydan C, Teater MR, Xia M, Farinha P, Takata K, Chu CS, Jiang Y, Eagles J, Passerini V, Tang Z, Rivas MA, Weigert O, ... ... Melnick AM, et al. Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment. Nature Communications. 15: 2879. PMID 38570506 DOI: 10.1038/s41467-024-47012-1 | 0.328 | |||
| 2024 | Deng Q, Lakra P, Gou P, Yang H, Meydan C, Teater M, Chin C, Zhang W, Dinh T, Hussein U, Li X, Rojas E, Liu W, Reville PK, Kizhakeyil A, ... ... Melnick A, et al. SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. Cancer Cell. PMID 38458188 DOI: 10.1016/j.ccell.2024.02.011 | 0.359 | |||
| 2024 | Barisic D, Chin CR, Meydan C, Teater M, Tsialta I, Mlynarczyk C, Chadburn A, Wang X, Sarkozy M, Xia M, Carson SE, Raggiri S, Debek S, Pelzer B, Durmaz C, ... ... Melnick A, et al. ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis. Cancer Cell. PMID 38458187 DOI: 10.1016/j.ccell.2024.02.010 | 0.329 | |||
| 2023 | Safa FM, Rasmussen T, Fontan L, Xia M, Melnick A, Wiestner A, Lobelle-Rich P, Burger JA, Mouawad Y, Safah H, Flemington EK, Saba NS. Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application. Haematologica. PMID 37767562 DOI: 10.3324/haematol.2023.283178 | 0.376 | |||
| 2023 | Shah SB, Carlson CR, Lai K, Zhong Z, Marsico G, Lee KM, Félix Vélez NE, Abeles EB, Allam M, Hu T, Walter LD, Martin KE, Gandhi K, Butler SD, Puri R, ... ... Melnick A, et al. Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomas. Nature Materials. PMID 36928381 DOI: 10.1038/s41563-023-01495-3 | 0.34 | |||
| 2023 | Leca J, Lemonnier F, Meydan C, Foox J, El Ghamrasni S, Mboumba DL, Duncan GS, Fortin J, Sakamoto T, Tobin C, Hodgson K, Haight J, Smith LK, Elia AJ, Butler D, ... Melnick A, et al. IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment. Cancer Cell. PMID 36736318 DOI: 10.1016/j.ccell.2023.01.003 | 0.314 | |||
| 2023 | Mlynarczyk C, Teater M, Pae J, Chin CR, Wang L, Arulraj T, Barisic D, Papin A, Hoehn KB, Kots E, Ersching J, Bandyopadhyay A, Barin E, Poh HX, Evans CM, ... ... Melnick A, et al. mutation yields supercompetitive B cells primed for malignant transformation. Science (New York, N.Y.). 379: eabj7412. PMID 36656933 DOI: 10.1126/science.abj7412 | 0.309 | |||
| 2023 | Fortin J, Chiang MF, Meydan C, Foox J, Ramachandran P, Leca J, Lemonnier F, Li WY, Gams MS, Sakamoto T, Chu M, Tobin C, Laugesen E, Robinson TM, You-Ten A, ... ... Melnick AM, et al. Distinct and opposite effects of leukemogenic and mutations in hematopoietic stem and progenitor cells. Proceedings of the National Academy of Sciences of the United States of America. 120: e2208176120. PMID 36652477 DOI: 10.1073/pnas.2208176120 | 0.304 | |||
| 2022 | Flumann R, Hansen J, Pelzer BW, Nieper P, Lohmann T, Kisis I, Riet T, Kohlhas V, Nguyen PH, Peifer M, Abedpour N, Bosco G, Thomas RK, Kochanek M, Knufer J, ... ... Melnick AM, et al. Distinct genetically-determined origins of Myd88/Bcl2-driven aggressive lymphoma rationalize targeted therapeutic intervention strategies. Blood Cancer Discovery. PMID 36346827 DOI: 10.1158/2643-3230.BCD-22-0007 | 0.36 | |||
| 2022 | Venturutti L, Rivas MA, Pelzer BW, Flumann R, Hansen J, Karagiannidis I, Xia M, McNally DR, Isshiki Y, Lytle A, Teater M, Chin CR, Meydan C, Knittel G, Ricker E, ... ... Melnick AM, et al. An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas. Cancer Discovery. PMID 36264161 DOI: 10.1158/2159-8290.CD-22-0561 | 0.354 | |||
| 2022 | Erazo T, Evans CM, Zakheim D, Chu KL, Refermat AY, Asgari Z, Yang X, Da Silva Ferreira M, Mehta S, Russo MV, Knezevic A, Zhang XP, Chen Z, Fennell M, Garippa R, ... Melnick AM, et al. TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma. Nature Communications. 13: 5676. PMID 36167829 DOI: 10.1038/s41467-022-33137-8 | 0.333 | |||
| 2022 | Morschhauser F, Salles G, Batlevi CL, Tilly H, Chaidos A, Phillips T, Burke J, Melnick A. Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas. Blood Reviews. 100988. PMID 35851487 DOI: 10.1016/j.blre.2022.100988 | 0.362 | |||
| 2022 | Hu Q, Xu T, Zhang M, Zhang H, Liu Y, Li HB, Chen C, Zheng J, Zhang Z, Li F, Shen N, Zhang W, Melnick A, Huang C. Diverging regulation of Bach2 protein and RNA expression determine cell fate in early B cell response. Cell Reports. 40: 111035. PMID 35793628 DOI: 10.1016/j.celrep.2022.111035 | 0.332 | |||
| 2022 | Papin A, Cesarman E, Melnick A. 3D chromosomal architecture in germinal center B cells and its alterations in lymphomagenesis. Current Opinion in Genetics & Development. 74: 101915. PMID 35550952 DOI: 10.1016/j.gde.2022.101915 | 0.318 | |||
| 2022 | Leung W, Teater M, Durmaz C, Meydan C, Chivu AG, Chadburn A, Rice EJ, Muley A, Camarillo JM, Arivalagan J, Li Z, Flowers CR, Kelleher NL, Danko CG, Imielinski M, ... Melnick AM, et al. SETD2 haploinsufficiency enhances germinal center-associated AICDA somatic hypermutation to drive B cell lymphomagenesis. Cancer Discovery. PMID 35443279 DOI: 10.1158/2159-8290.CD-21-1514 | 0.317 | |||
| 2022 | Takata K, Chong LC, Ennishi D, Aoki T, Li MY, Thakur A, Healy S, Viganò E, Dao T, Kwon D, Duns G, Nielsen JS, Ben-Neriah S, Tse E, Hung SS, ... Melnick AM, et al. Tumor associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B-cell lymphoma. The Journal of Clinical Investigation. PMID 35380993 DOI: 10.1172/JCI145343 | 0.371 | |||
| 2022 | Serganova I, Chakraborty S, Yamshon S, Isshiki Y, Bucktrout R, Melnick A, Béguelin W, Zappasodi R. Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies. Frontiers in Cell and Developmental Biology. 9: 805195. PMID 35071240 DOI: 10.3389/fcell.2021.805195 | 0.326 | |||
| 2021 | Giefing M, Gearhart MD, Schneider M, Overbeck B, Klapper W, Hartmann S, Ustaszewski A, Weniger MA, Wiehle L, Hansmann ML, Melnick A, Béguelin W, Sundström C, Küppers R, Bardwell VJ, et al. Loss of function mutations of in classical Hodgkin lymphoma. Leukemia & Lymphoma. 1-11. PMID 34957890 DOI: 10.1080/10428194.2021.2015587 | 0.393 | |||
| 2021 | Seshadri MR, Melnick AM. Targeting MALT1 for the treatment of diffuse large B-cell lymphoma. Leukemia & Lymphoma. 1-10. PMID 34783281 DOI: 10.1080/10428194.2021.1999444 | 0.344 | |||
| 2021 | Rivas MA, Durmaz C, Kloetgen A, Chin CR, Chen Z, Bhinder B, Koren A, Viny AD, Scharer CD, Boss JM, Elemento O, Mason CE, Melnick AM. Cohesin Core Complex Gene Dosage Contributes to Germinal Center Derived Lymphoma Phenotypes and Outcomes. Frontiers in Immunology. 12: 688493. PMID 34621263 DOI: 10.3389/fimmu.2021.688493 | 0.424 | |||
| 2021 | Soshnev AA, Allis CD, Cesarman E, Melnick AM. Histone H1 mutations in lymphoma: a link(er) between chromatin organization, developmental reprogramming, and cancer. Cancer Research. PMID 34580064 DOI: 10.1158/0008-5472.CAN-21-2619 | 0.301 | |||
| 2021 | Doane AS, Chu CS, Di Giammartino DC, Rivas MA, Hellmuth JC, Jiang Y, Yusufova N, Alonso A, Roeder RG, Apostolou E, Melnick AM, Elemento O. OCT2 pre-positioning facilitates cell fate transition and chromatin architecture changes in humoral immunity. Nature Immunology. PMID 34556886 DOI: 10.1038/s41590-021-01025-w | 0.307 | |||
| 2021 | Flümann R, Rehkämper T, Nieper P, Pfeiffer P, Holzem A, Klein S, Bhatia S, Kochanek M, Kisis I, Pelzer BW, Ahlert H, Hauer J, da Palma Guerreiro A, Ryan JA, Reimann M, ... ... Melnick AM, et al. An Autochthonous Mouse Model of - and -Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities. Cancer Discovery. 2: 70-91. PMID 34233267 DOI: 10.1158/2643-3230.BCD-19-0059 | 0.313 | |||
| 2021 | Zee BM, Poels KE, Yao CH, Kawabata KC, Wu G, Duy C, Jacobus WD, Senior E, Endress JE, Jambhekar A, Lovitch SB, Ma J, Dhall A, Harris IS, Blanco MA, ... ... Melnick A, et al. Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia. Iscience. 24: 102651. PMID 34151238 DOI: 10.1016/j.isci.2021.102651 | 0.547 | |||
| 2021 | Valcárcel LV, Amundarain A, Kulis M, Charalampopoulou S, Melnick A, San Miguel J, Martín-Subero JI, Planes FJ, Agirre X, Prosper F. Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma. Leukemia. PMID 33972667 DOI: 10.1038/s41375-021-01263-9 | 0.322 | |||
| 2021 | Ai Y, Hwang L, MacKerell AD, Melnick A, Xue F. Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond. Journal of Medicinal Chemistry. PMID 33844535 DOI: 10.1021/acs.jmedchem.0c01686 | 0.347 | |||
| 2021 | Mulet-Lazaro R, van Herk S, Erpelinck CAJ, Bindels E, Sanders MA, Vermeulen C, Renkens I, Valk P, Melnick A, de Ridder J, Rehli M, Gebhard C, Delwel R, Wouters BJ. Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double mutant AML. Blood. PMID 33831168 DOI: 10.1182/blood.2020009244 | 0.335 | |||
| 2021 | Heward JA, Koniali L, D'Avola A, Close K, Yeomans A, Philpott M, Dunford JE, Rahim T, Al Seraihi AF, Wang J, Korfi K, Araf S, Iqbal S, Bewicke-Copley F, Kumar E, ... Melnick A, et al. KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. Blood. PMID 33786580 DOI: 10.1182/blood.2020008743 | 0.361 | |||
| 2021 | Kotlov N, Bagaev A, Revuelta MV, Phillip JM, Cacciapuoti MT, Antysheva Z, Svekolkin V, Tikhonova E, Miheecheva N, Kuzkina N, Nos G, Tabbo F, Frenkel F, Ghione P, Tsiper M, ... ... Melnick AM, et al. Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures. Cancer Discovery. PMID 33541860 DOI: 10.1158/2159-8290.CD-20-0839 | 0.303 | |||
| 2021 | Duy C, Li M, Teater M, Meydan C, Garrett-Bakelman FE, Lee TC, Chin CR, Durmaz C, Kawabata KC, Dhimolea E, Mitsiades CS, Doehner H, D'Andrea RJ, Becker MW, Paietta EM, ... ... Melnick AM, et al. Chemotherapy induces senescence-like resilient cells capable of initiating AML recurrence. Cancer Discovery. PMID 33500244 DOI: 10.1158/2159-8290.CD-20-1375 | 0.341 | |||
| 2021 | Flümann R, Rehkämper T, Nieper P, Pfeiffer P, Holzem A, Klein S, Bhatia S, Kochanek M, Kisis I, Pelzer BW, Ahlert H, Hauer J, da Palma Guerreiro A, Ryan JA, Reimann M, ... ... Melnick AM, et al. An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities. Blood Cancer Discovery. 2: 70-91. PMID 33447829 DOI: 10.1158/2643-3230.BCD-19-0059 | 0.323 | |||
| 2021 | Rivas MA, Meydan C, Chin CR, Challman MF, Kim D, Bhinder B, Kloetgen A, Viny AD, Teater MR, McNally DR, Doane AS, Béguelin W, Fernández MTC, Shen H, Wang X, ... ... Melnick AM, et al. Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation. Nature Immunology. PMID 33432228 DOI: 10.1038/s41590-020-00827-8 | 0.353 | |||
| 2021 | Isshiki Y, Melnick A. Epigenetic mechanisms of therapy resistance in diffuse large B cell lymphoma (DLBCL). Current Cancer Drug Targets. PMID 33413063 DOI: 10.2174/1568009620666210106122750 | 0.353 | |||
| 2021 | Pae J, Ersching J, Castro TBR, Schips M, Mesin L, Allon SJ, Ordovas-Montanes J, Mlynarczyk C, Melnick A, Efeyan A, Shalek AK, Meyer-Hermann M, Victora GD. Cyclin D3 drives inertial cell cycling in dark zone germinal center B cells. The Journal of Experimental Medicine. 218. PMID 33332554 DOI: 10.1084/jem.20201699 | 0.326 | |||
| 2021 | Venturutti L, Melnick AM. The Role of Epigenetic Mechanisms in B Cell Lymphoma Pathogenesis Annual Review of Cancer Biology. 5: 311-330. DOI: 10.1146/annurev-cancerbio-060820-125304 | 0.346 | |||
| 2020 | Parsa S, Ortega-Molina A, Ying HY, Jiang M, Teater M, Wang J, Zhao C, Reznik E, Pasion JP, Kuo D, Mohan P, Wang S, Camarillo JM, Thomas PM, Jain N, ... ... Melnick AM, et al. The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing. Nature Cancer. 1: 653-664. PMID 33569544 DOI: 10.1038/s43018-020-0080-0 | 0.342 | |||
| 2020 | Yusufova N, Kloetgen A, Teater M, Osunsade A, Camarillo JM, Chin CR, Doane AS, Venters BJ, Portillo-Ledesma S, Conway J, Phillip JM, Elemento O, Scott DW, Béguelin W, Licht JD, ... ... Melnick AM, et al. Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. Nature. PMID 33299181 DOI: 10.1038/s41586-020-3017-y | 0.519 | |||
| 2020 | Chu CS, Hellmuth JC, Singh R, Ying HY, Skrabanek L, Teater MR, Doane AS, Elemento O, Melnick AM, Roeder RG. Unique Immune Cell Coactivators Specify Locus Control Region Function and Cell Stage. Molecular Cell. PMID 33232656 DOI: 10.1016/j.molcel.2020.10.036 | 0.309 | |||
| 2020 | Scholze H, Stephenson RE, Reynolds R, Shah S, Puri R, Butler SD, Trujillo-Alonso V, Teater MR, van Besien H, Gibbs-Curtis D, Ueno H, Parvin S, Letai A, Mathew S, Singh A, ... ... Melnick A, et al. Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. Blood Advances. 4: 5226-5231. PMID 33104794 DOI: 10.1182/bloodadvances.2020002580 | 0.356 | |||
| 2020 | Venturutti L, Melnick A. The dangers of déjà vu: Memory B-cells as the cell-of-origin of ABC-DLBCLs. Blood. PMID 32932517 DOI: 10.1182/Blood.2020005857 | 0.447 | |||
| 2020 | Kawabata KC, Zong H, Meydan C, Wyman S, Wouters BJ, Sugita M, Goswami S, Albert M, Yip W, Roboz GJ, Chen Z, Delwel R, Carroll MP, Mason C, Melnick A, et al. BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells. Blood. PMID 32911532 DOI: 10.1182/Blood.2019001745 | 0.491 | |||
| 2020 | Ordonez R, Kulis M, Russinol N, Chapaprieta V, Carrasco-Leon A, Garcia-Torre B, Charampopoulou S, Clot G, Beekman R, Meydan C, Duran-Ferrer M, Verdaguer-Dot N, Vilarrasa-Blasi R, Soler-Vila P, Garate L, ... ... Melnick A, et al. Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma. Genome Research. PMID 32820006 DOI: 10.1101/Gr.265520.120 | 0.606 | |||
| 2020 | Fontan Gabas L, Goldstein RL, Casalena G, Durant M, Teater MR, Wilson J, Phillip JM, Xia M, Shah S, Us I, Shinglot H, Singh A, Inghirami GG, Melnick A. Identification of MALT1 Feedback Mechanisms Enables Rational Design of Potent Anti-Lymphoma Regimens for ABC-DLBCL. Blood. PMID 32785655 DOI: 10.1182/Blood.2019004713 | 0.436 | |||
| 2020 | Venturutti L, Teater M, Zhai A, Chadburn A, Babiker L, Kim D, Béguelin W, Lee TC, Kim Y, Chin CR, Yewdell WT, Raught B, Phillip JM, Jiang Y, Staudt LM, ... Melnick AM, et al. TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. Cell. PMID 32619424 DOI: 10.1016/J.Cell.2020.05.049 | 0.347 | |||
| 2020 | Rosikiewicz W, Chen X, Dominguez PM, Ghamlouch H, Aoufouchi S, Bernard OA, Melnick A, Li S. TET2 deficiency reprograms the germinal center B cell epigenome and silences genes linked to lymphomagenesis. Science Advances. 6: eaay5872. PMID 32596441 DOI: 10.1126/Sciadv.Aay5872 | 0.492 | |||
| 2020 | Béguelin W, Teater M, Meydan C, Hoehn KB, Phillip JM, Soshnev AA, Venturutti L, Rivas MA, Calvo-Fernández MT, Gutierrez J, Camarillo JM, Takata K, Tarte K, Kelleher NL, Steidl C, ... ... Melnick AM, et al. Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response. Cancer Cell. 37: 655-673.e11. PMID 32396861 DOI: 10.1016/J.Ccell.2020.04.004 | 0.339 | |||
| 2020 | Fabre MS, Stanton NM, Slatter TL, Lee S, Senanayake D, Gordon RMA, Castro ML, Rowe MR, Taha A, Royds JA, Hung N, Melnick AM, McConnell MJ. The oncogene BCL6 is up-regulated in glioblastoma in response to DNA damage, and drives survival after therapy. Plos One. 15: e0231470. PMID 32320427 DOI: 10.1371/journal.pone.0231470 | 0.333 | |||
| 2020 | Duy C, Béguelin W, Melnick A. Epigenetic Mechanisms in Leukemias and Lymphomas. Cold Spring Harbor Perspectives in Medicine. PMID 32014848 DOI: 10.1101/Cshperspect.A034959 | 0.471 | |||
| 2020 | Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, Yang H, Singh S, Ying HY, Chu CS, Ma MCJ, Toska E, Alig S, Durant M, de Stanchina E, ... ... Melnick AM, et al. Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma. Cancer Discovery. PMID 31915197 DOI: 10.1158/2159-8290.Cd-19-0116 | 0.578 | |||
| 2020 | Xia M, David L, Teater M, Onder O, Elenitoba-Johnson KSJ, Fontan L, Wu H, Melnick A. BCL10 Gain-of-Function Mutations Aberrantly Induce Canonical and Non-Canonical NF-Kb Activation and Resistance to Ibrutinib in ABC-DLBCL Blood. 136: 2-3. DOI: 10.1182/blood-2020-141363 | 0.302 | |||
| 2020 | Takata K, Chong LC, Ennishi D, Thakur A, Healy S, Viganò E, Dao T, Nielsen JS, Ben-Neriah S, Aoki T, Tse E, Hung S, Li MY, Boyle M, Mun SS, ... Melnick A, et al. The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma Blood. 136: 34-34. DOI: 10.1182/BLOOD-2020-141168 | 0.351 | |||
| 2019 | Hellmuth JC, Chu CS, Singh R, Skrabanek LA, Doane A, Elemento O, Roeder RG, Melnick A. An OCT2 / OCA-B / MEF2B Ternary Complex Controls the Activity and Architecture of an Essential Locus Control Region for Normal and Malignant Germinal Center B-Cells. Blood. 134: 24. PMID 31723990 DOI: 10.1182/Blood-2019-130692 | 0.338 | |||
| 2019 | Yusufova N, Teater MR, Soshnev A, Kloetgen A, Osunsade A, Conway J, Doane A, Skoultchi A, Tsirigos A, David Y, Allis CD, Cesarman E, Melnick A. Histone 1 Mutations Drive Lymphomagenesis By Inducing Primitive Stem Cell Functions and Epigenetic Instructions through Profound 3D Re-Organization of the B-Cell Genome. Blood. 134: 23. PMID 31723979 DOI: 10.1182/Blood-2019-127774 | 0.402 | |||
| 2019 | Fong JY, Pignata L, Goy PA, Kawabata KC, Lee SC, Koh CM, Musiani D, Massignani E, Kotini AG, Penson A, Wun CM, Shen Y, Schwarz M, Low DH, Rialdi A, ... ... Melnick A, et al. Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation. Cancer Cell. 36: 194-209.e9. PMID 31408619 DOI: 10.1016/J.Ccell.2019.07.003 | 0.375 | |||
| 2019 | Hurtz C, Chan LN, Geng H, Ballabio E, Xiao G, Deb G, Khoury H, Chen CW, Armstrong SA, Chen J, Ernst P, Melnick A, Milne T, Müschen M. Rationale for targeting BCL6 in -rearranged acute lymphoblastic leukemia. Genes & Development. PMID 31395741 DOI: 10.1101/Gad.327593.119 | 0.496 | |||
| 2019 | Li M, Chiang YL, Lyssiotis CA, Teater MR, Hong JY, Shen H, Wang L, Hu J, Jing H, Chen Z, Jain N, Duy C, Mistry SJ, Cerchietti L, Cross JR, ... ... Melnick AM, et al. Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis. Cancer Cell. 35: 916-931.e9. PMID 31185214 DOI: 10.1016/J.Ccell.2019.05.002 | 0.333 | |||
| 2019 | Duy C, Teater M, Garrett-Bakelman FE, Lee TC, Meydan C, Glass JL, Li M, Hellmuth JC, Mohammad HP, Smitheman KN, Shih AH, Abdel-Wahab O, Tallman MS, Guzman ML, Muench D, ... ... Melnick AM, et al. Rational targeting of cooperating layers of the epigenome yields enhanced therapeutic efficacy against AML. Cancer Discovery. PMID 31076479 DOI: 10.1158/2159-8290.Cd-19-0106 | 0.332 | |||
| 2019 | Rivas MA, Melnick AM. Role of chromosomal architecture in germinal center B cells and lymphomagenesis. Current Opinion in Hematology. PMID 31033702 DOI: 10.1097/MOH.0000000000000505 | 0.306 | |||
| 2019 | Pastore A, Gaiti F, Lu SX, Brand RM, Kulm S, Chaligne R, Gu H, Huang KY, Stamenova EK, Béguelin W, Jiang Y, Schulman RC, Kim KT, Alonso A, Allan JN, ... ... Melnick AM, et al. Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL. Nature Communications. 10: 1874. PMID 31015400 DOI: 10.1038/S41467-019-09645-5 | 0.342 | |||
| 2019 | Pascual M, Mena-Varas M, Robles EF, Garcia-Barchino MJ, Panizo C, Hervas-Stubbs S, Alignani D, Sagardoy A, Martínez JI, Bunting KL, Meier S, Sagaert X, Bagnara D, Guruceaga E, Blanco O, ... ... Melnick A, et al. PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B cell diffuse large B-cell lymphomas. Blood. PMID 30975638 DOI: 10.1182/Blood.2018889931 | 0.395 | |||
| 2019 | Hatcher JM, Du G, Fontán L, Us I, Qiao Q, Chennamadhavuni S, Shao J, Wu H, Melnick A, Gray NS, Scott DA. Peptide-based covalent inhibitors of MALT1 paracaspase. Bioorganic & Medicinal Chemistry Letters. PMID 30954428 DOI: 10.1016/J.Bmcl.2019.03.046 | 0.308 | |||
| 2019 | Mlynarczyk C, Fontán L, Melnick A. Germinal center-derived lymphomas: The darkest side of humoral immunity. Immunological Reviews. 288: 214-239. PMID 30874354 DOI: 10.1111/Imr.12755 | 0.456 | |||
| 2019 | Sermer D, Pasqualucci L, Wendel HG, Melnick A, Younes A. Emerging epigenetic-modulating therapies in lymphoma. Nature Reviews. Clinical Oncology. PMID 30837715 DOI: 10.1038/S41571-019-0190-8 | 0.434 | |||
| 2019 | Agirre X, Meydan C, Jiang Y, Garate L, Doane AS, Li Z, Verma A, Paiva B, Martín-Subero JI, Elemento O, Mason CE, Prosper F, Melnick A. Long non-coding RNAs discriminate the stages and gene regulatory states of human humoral immune response. Nature Communications. 10: 821. PMID 30778059 DOI: 10.1038/S41467-019-08679-Z | 0.369 | |||
| 2019 | Ennishi D, Takata K, Beguelin W, Duns G, Mottok A, Farinha P, Bashashati A, Saberi S, Boyle M, Meissner B, Ben-Neriah S, Woolcock BW, Telenius A, Lai D, Teater M, ... ... Melnick AM, et al. Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. Cancer Discovery. PMID 30705065 DOI: 10.1158/2159-8290.Cd-18-1090 | 0.302 | |||
| 2019 | Hatzi K, Geng H, Doane AS, Meydan C, LaRiviere R, Cardenas M, Duy C, Shen H, Vidal MNC, Baslan T, Mohammad HP, Kruger RG, Shaknovich R, Haberman AM, Inghirami G, ... ... Melnick AM, et al. Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis. Nature Immunology. 20: 86-96. PMID 30538335 DOI: 10.1038/S41590-018-0273-1 | 0.365 | |||
| 2019 | Chan LN, Hurtz C, Geng H, Ballabio E, Xiao G, Deb G, Khoury H, Armstrong SA, Ernst P, Melnick A, Milne TA, Müschen M. Rationale for Targeting BCL6 in MLL-Rearranged B-ALL Blood. 134: 1239-1239. DOI: 10.1182/Blood-2019-131565 | 0.476 | |||
| 2019 | Saba NS, Meyers J, Fontan L, Melnick A, Wiestner A, Lobelle-Rich P, Kim E, Burger JA, Mouawad Y, Deininger PL, Socola F, Safah H, Flemington EK. The Paracaspase MALT1 Acts Independently of Pre-B-Cell Receptor Signaling As a Key Factor in Leukemic Cell Survival in Precursor B-Cell Acute Lymphoblastic Leukemia Blood. 134: 1288-1288. DOI: 10.1182/Blood-2019-131376 | 0.413 | |||
| 2019 | Lee J, Kume K, Chen Z, Xiao G, Cosgun KNN, Chen L, Chan LN, Klemm L, Chen CD, Ma N, Chan WC, Forman SJ, Zammarchi F, Van Berkel P, Melnick A, et al. Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling Blood. 134: 393-393. DOI: 10.1182/Blood-2019-131270 | 0.377 | |||
| 2019 | Fontan L, Hatcher J, Scott D, Qiao Q, Us I, Du G, Durant M, Wilson J, Wu H, Gray N, Melnick A. Chemically Induced Degradation of MALT1 to Treat B-Cell Lymphomas Blood. 134: 2073-2073. DOI: 10.1182/Blood-2019-130666 | 0.447 | |||
| 2019 | Fontan L, Durant M, Goldstein R, Teater MR, Casalena G, Xia M, Wilson J, Us I, Inghirami G, Melnick A. Mapping MALT1 Signaling Connectivity Unveils Novel B-Cell Feedback Mechanisms Directing Assembly of Potent Anti-Lymphoma Regimens Blood. 134: 173-173. DOI: 10.1182/Blood-2019-130516 | 0.359 | |||
| 2019 | Gibbs D, Van Besien H, Regan S, Singh A, Teater M, Cesarman E, Melnick A, Roth LG. Combined EZH2 and BCL2 Inhibitors As Precision Therapy for Genetically Defined DLBCL Subtypes Blood. 134: 304-304. DOI: 10.1182/Blood-2019-126790 | 0.436 | |||
| 2019 | Ordoñez R, Kulis M, Russiñol N, Chapaprieta V, Beekman R, Meydan C, Duran-Ferrer M, Verdaguer-Dot N, Clot G, Vilarrasa-Blasi R, Garate L, Miranda E, Carrasco A, Ezponda T, Martens JH, ... ... Melnick A, et al. CHROMATIN ACTIVATION AS A UNIFYING PRINCIPLE UNDERLYING PATHOGENIC MECHANISMS IN MULTIPLE MYELOMA Hemasphere. 3: 236. DOI: 10.1097/01.HS9.0000560560.72691.D3 | 0.448 | |||
| 2019 | Melnick A. Precision Epigenetic Therapy For B‐Cell Lymphoma Hematological Oncology. 37: 34-34. DOI: 10.1002/Hon.2_2629 | 0.303 | |||
| 2018 | Duy C, Melnick A. Untangling the Role of Polycomb Complexes in Chemotherapy Resistance. Cancer Discovery. 8: 1348-1351. PMID 30385522 DOI: 10.1158/2159-8290.Cd-18-1080 | 0.396 | |||
| 2018 | Paz K, Flynn R, Du J, Qi J, Luznik L, Maillard I, MacDonald KP, Hill GR, Serody JS, Murphy WJ, Sage PT, Sharpe AH, Miklos D, Culter CS, Koreth J, ... ... Melnick AM, et al. Small-molecule BCL6 inhibitor effectively treats mice with non-sclerodermatous chronic graft-versus-host disease. Blood. PMID 30279226 DOI: 10.1182/Blood-2018-03-839993 | 0.328 | |||
| 2018 | Dominguez PM, Ghamlouch H, Rosikiewicz W, Kumar P, Béguelin W, Fontan L, Rivas MA, Pawlikowska P, Armand M, Mouly E, Torres-Martin M, Doane AS, Calvo Fernandez MT, Durant M, Della-Valle V, ... ... Melnick AM, et al. TET2 deficiency causes germinal center hyperplasia, impairs plasma cell differentiation and promotes B-cell lymphomagenesis. Cancer Discovery. PMID 30274972 DOI: 10.1158/2159-8290.Cd-18-0657 | 0.34 | |||
| 2018 | Lu X, Fernando T, Lossos C, Yusufova N, Liu F, Fontán L, Durant M, Geng H, Melnick J, Luo Y, Vega F, Moy V, Inghirami G, Nimer S, Melnick AM, et al. PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. Blood. PMID 30082494 DOI: 10.1182/Blood-2018-02-831438 | 0.39 | |||
| 2018 | Pronier E, Bowman RL, Ahn J, Glass J, Kandoth C, Merlinsky TR, Whitfield JT, Durham BH, Gruet A, Hanasoge Somasundara AV, Rampal R, Melnick A, Koche RP, Taylor BS, Levine RL. Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis. Blood. PMID 30064973 DOI: 10.1182/Blood-2018-03-837468 | 0.423 | |||
| 2018 | Fontán L, Qiao Q, Hatcher JM, Casalena G, Us I, Teater M, Durant M, Du G, Xia M, Bilchuk N, Chennamadhavuni S, Palladino G, Inghirami G, Philippar U, Wu H, ... ... Melnick A, et al. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. The Journal of Clinical Investigation. PMID 30024860 DOI: 10.1172/Jci99436 | 0.449 | |||
| 2018 | Cheng H, Linhares B, Yu W, Cardenas MG, Ai Y, Jiang W, Winkler A, Cohen S, Melnick A, MacKerell AD, Cierpicki T, Xue F. Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 (BCL6) BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design. Journal of Medicinal Chemistry. PMID 29969259 DOI: 10.1021/Acs.Jmedchem.8B00040 | 0.367 | |||
| 2018 | Maes T, Mascaró C, Tirapu I, Estiarte A, Ciceri F, Lunardi S, Guibourt N, Perdones A, Lufino MMP, Somervaille TCP, Wiseman DH, Duy C, Melnick A, Willekens C, Ortega A, et al. ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia. Cancer Cell. PMID 29502954 DOI: 10.1016/J.Ccell.2018.02.002 | 0.436 | |||
| 2018 | Brown FC, Still E, Koche RP, Yim CY, Takao S, Cifani P, Reed C, Gunasekera S, Ficarro SB, Romanienko P, Mark W, McCarthy C, de Stanchina E, Gonen M, Seshan V, ... ... Melnick A, et al. MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia. Cancer Discovery. PMID 29431698 DOI: 10.1158/2159-8290.Cd-17-1271 | 0.387 | |||
| 2018 | Teater M, Dominguez PM, Redmond D, Chen Z, Ennishi D, Scott DW, Cimmino L, Ghione P, Chaudhuri J, Gascoyne RD, Aifantis I, Inghirami G, Elemento O, Melnick A, Shaknovich R. AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. Nature Communications. 9: 222. PMID 29335468 DOI: 10.1038/S41467-017-02595-W | 0.479 | |||
| 2018 | Phillip JM, Calvo Vidal MN, Revuelta MV, Zamponi N, Sloan S, Pera Gresely B, Fernando T, Tam W, Inghirami G, Bonassar L, Melnick AM, Cerchietti L. Heat Shock Factor 1 Reprograms the DLBCL Microenvironment to Evade Immune Surveillance and Support Tumor Growth Blood. 132: 2854-2854. DOI: 10.1182/Blood-2018-99-117774 | 0.326 | |||
| 2018 | Melnick A. Abstract IA11: Epigenetic mechanisms in pathogenesis and targeted therapy for B-cell lymphomas Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Tcm17-Ia11 | 0.498 | |||
| 2018 | Mondello P, Teater M, Fontan L, Durant M, Stanchina Ed, Inghirami G, Green M, Melnick A. Abstract 797: Targeting HDAC3 reactivates immunosurveillance and enhances immunocheckpoint activity in B-cell lymphoma Cancer Research. 78: 797-797. DOI: 10.1158/1538-7445.Am2018-797 | 0.525 | |||
| 2018 | Lee J, Geng H, Chen Z, Xiao G, Cosgun KN, Zammarchi F, Berkel PV, Melnick A, Paietta E, Muschen M. Abstract 2983: CD25 enables oncogenic BCR- and TCR-signaling and represents a therapeutic target in lymphoblastic malignancies Cancer Research. 78: 2983-2983. DOI: 10.1158/1538-7445.Am2018-2983 | 0.385 | |||
| 2017 | Kunimoto H, Meydan C, Nazir A, Whitfield J, Shank K, Rapaport F, Maher R, Pronier E, Meyer SC, Garrett-Bakelman FE, Tallman M, Melnick A, Levine RL, Shih AH. Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity. Cancer Cell. PMID 29275866 DOI: 10.1016/J.Ccell.2017.11.012 | 0.401 | |||
| 2017 | Béguelin W, Rivas MA, Calvo Fernández MT, Teater M, Purwada A, Redmond D, Shen H, Challman MF, Elemento O, Singh A, Melnick AM. EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop. Nature Communications. 8: 877. PMID 29026085 DOI: 10.1038/S41467-017-01029-X | 0.338 | |||
| 2017 | Saba NS, Wong DH, Tanios G, Iyer JR, Lobelle-Rich P, Dadashian EL, Liu D, Fontan L, Flemington EK, Nichols CM, Underbayev C, Safah H, Melnick A, Wiestner A, Herman SEM. MALT1 inhibition is efficacious in both naïve and ibrutinib-resistant chronic lymphocytic leukemia. Cancer Research. PMID 28993409 DOI: 10.1158/0008-5472.Can-17-2485 | 0.441 | |||
| 2017 | Teater M, Melnick A. Untangling the Web of Lymphoma Somatic Mutations. Cell. 171: 270-272. PMID 28985559 DOI: 10.1016/J.Cell.2017.09.031 | 0.358 | |||
| 2017 | Vu LP, Pickering BF, Cheng Y, Zaccara S, Nguyen D, Minuesa G, Chou T, Chow A, Saletore Y, MacKay M, Schulman J, Famulare C, Patel M, Klimek VM, Garrett-Bakelman FE, ... Melnick A, et al. The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nature Medicine. PMID 28920958 DOI: 10.1038/Nm.4416 | 0.43 | |||
| 2017 | Oricchio E, Katanayeva N, Donaldson MC, Sungalee S, Joyce PP, Béguelin W, Battistello E, Sanghvi VR, Jiang M, Jiang Y, Teater M, Parmigiani A, Budanov AV, Chan FC, Shah SP, ... ... Melnick AM, et al. Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma. Science Translational Medicine. 9. PMID 28659443 DOI: 10.1126/Scitranslmed.Aak9969 | 0.31 | |||
| 2017 | Vu LP, Prieto C, Amin EM, Chhangawala S, Krivtsov A, Calvo-Vidal MN, Chou T, Chow A, Minuesa G, Park SM, Barlowe TS, Taggart J, Tivnan P, Deering RP, Chu LP, ... ... Melnick A, et al. Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nature Genetics. PMID 28436985 DOI: 10.1038/Ng.3854 | 0.44 | |||
| 2017 | Glass J, Hassane DC, Wouters B, Kunimoto H, Avellino R, Garrett-Bakelman FE, Guryanova OA, Bowman R, Redlich S, Intlekofer A, Meydan C, Qin T, Fall MP, Alonso A, Guzman ML, ... ... Melnick A, et al. Epigenetic Identity in AML Depends on Disruption of Non-promoter Regulatory Elements and is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. Cancer Discovery. PMID 28408400 DOI: 10.1158/2159-8290.Cd-16-1032 | 0.403 | |||
| 2017 | Gascoyne RD, Nadel B, Pasqualucci L, Fitzgibbon J, Payton JE, Melnick A, Weigert O, Tarte K, Gribben JG, Friedberg JW, Seymour JF, Cavalli F, Zucca E. Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015. Hematological Oncology. PMID 28378425 DOI: 10.1002/Hon.2411 | 0.36 | |||
| 2017 | Valls E, Lobry C, Geng H, Wang L, Cardenas M, Rivas M, Cerchietti L, Oh P, Yang SN, Oswald E, Graham CW, Jiang Y, Hatzi K, Agirre X, Perkey E, ... Melnick A, et al. BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. Cancer Discovery. PMID 28232365 DOI: 10.1158/2159-8290.Cd-16-1189 | 0.484 | |||
| 2017 | Shih AH, Meydan C, Shank K, Garrett-Bakelman FE, Ward PS, Intlekofer A, Nazir A, Stein E, Knapp K, Glass J, Travins J, Straley K, Gliser C, Mason C, Yen K, ... ... Melnick A, et al. Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia. Cancer Discovery. PMID 28193779 DOI: 10.1158/2159-8290.Cd-16-1049 | 0.462 | |||
| 2017 | Kunimoto H, McKenney AS, Meydan C, Shank K, Nazir A, Rapaport F, Durham B, Garrett-Bakelman FE, Pronier E, Shih AH, Melnick A, Chaudhuri J, Levine RL. Aid is a key regulator of myeloid/erythroid differentiation and DNA methylation in hematopoietic stem/progenitor cells. Blood. PMID 28077417 DOI: 10.1182/Blood-2016-06-721977 | 0.433 | |||
| 2017 | Vu LP, Pickering BF, Cheng Y, Sara Z, Nguyen D, Minuesa G, Chou T, Chow A, MacKay M, Famulare C, Patel M, Garret-Bakelman F, Melnick A, Carroll M, Mason C, et al. m6a Regulates Differentiation State and mRNA Translation in Myeloid Leukemia Blood. 130: 791-791. DOI: 10.1182/BLOOD.V130.SUPPL_1.791.791 | 0.414 | |||
| 2017 | Li M, Chiang Y, Lyssiotis C, Teater M, Shen H, Wang L, Hong JY, Jin H, Duy C, Mistry S, Cerchietti L, Cross J, Cantley L, Lin H, Melnick A. SIRT3 Is a Novel Metabolic Driver of and Therapeutic Target for Chemotherapy Resistant Dlbcls Blood. 130: 643-643. DOI: 10.1182/Blood.V130.Suppl_1.643.643 | 0.447 | |||
| 2017 | Vu L, Prieto C, Amin EM, Minuesa G, Chhangawala S, Vidal MC, Krivtsov A, Chou T, Chow A, Barlowe T, Taggart J, Tivnan P, Deering RP, Chu LP, Gonen M, ... Melnick A, et al. Abstract IA13: RNA regulators and the control of self-renewal Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Hemmal17-Ia13 | 0.479 | |||
| 2017 | Fachel AA, Jiang Y, Tam W, Muley AS, Meydan C, Agirre X, Melnick AM, Richards KL. Abstract 30: SOX9 enhancer regulator may play an oncogenic role in B-cell lymphomas Clinical Cancer Research. 23: 30-30. DOI: 10.1158/1557-3265.Hemmal17-30 | 0.445 | |||
| 2017 | Fontan L, Scott D, Hatcher J, Qiao Q, Us I, Casalena G, Bekkers M, Philippar U, Durant M, Chennamadhavuni S, Wu H, Gray N, Melnick A. Abstract LB-303: Substrate-mimetic covalent inhibitor of MALT1 is most effective against CARD11 mutant ABC-DLBCL Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-303 | 0.46 | |||
| 2017 | Venneti S, Bayliss J, Mukherjee P, Lu C, Jain S, Chung C, Martinez D, Sabari B, Margol A, Panwalkar P, Paroloia A, Pekmezci M, Eachin RM, Cieslik M, Tamrazi B, ... ... Melnick A, et al. Abstract 3863: A subset of poorly prognostic pediatric posterior fossa ependymomas exhibit lowered H3K27me3 and DNA hypomethylation and show epigenetic similarities with H3K27M mutant diffuse intrinsic pontine gliomas Cancer Research. 77: 3863-3863. DOI: 10.1158/1538-7445.Am2017-3863 | 0.384 | |||
| 2016 | Bayliss J, Mukherjee P, Lu C, Jain SU, Chung C, Martinez D, Sabari B, Margol AS, Panwalkar P, Parolia A, Pekmezci M, McEachin RC, Cieslik M, Tamrazi B, Garcia BA, ... ... Melnick A, et al. Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. Science Translational Medicine. 8: 366ra161. PMID 27881822 DOI: 10.1126/Scitranslmed.Aah6904 | 0.353 | |||
| 2016 | Cardenas MG, Oswald E, Yu W, Xue F, MacKerell AD, Melnick AM. The expanding role of the BCL6 oncoprotein as a cancer therapeutic target. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27881582 DOI: 10.1158/1078-0432.Ccr-16-2071 | 0.398 | |||
| 2016 | Jiang Y, Ortega-Molina A, Geng H, Ying HY, Hatzi K, Parsa S, McNally D, Wang L, Doane AS, Agirre Ena X, Teater M, Meydan C, Li Z, Poloway D, Wang S, ... ... Melnick AM, et al. CREBBP Inactivation Promotes the Development of HDAC3 Dependent Lymphomas. Cancer Discovery. PMID 27733359 DOI: 10.1158/2159-8290.Cd-16-0975 | 0.356 | |||
| 2016 | Rodina A, Wang T, Yan P, Gomes ED, Dunphy MP, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H, Caldas-Lopes E, Alpaugh M, Corben A, Riolo M, Beattie B, ... ... Melnick A, et al. The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature. PMID 27706135 DOI: 10.1038/Nature19807 | 0.333 | |||
| 2016 | Bunting KL, Soong TD, Singh R, Jiang Y, Béguelin W, Poloway DW, Swed BL, Hatzi K, Reisacher W, Teater M, Elemento O, Melnick AM. Multi-tiered Reorganization of the Genome during B Cell Affinity Maturation Anchored by a Germinal Center-Specific Locus Control Region. Immunity. PMID 27637145 DOI: 10.1016/J.Immuni.2016.08.012 | 0.344 | |||
| 2016 | Béguelin W, Teater M, Gearhart MD, Calvo Fernández MT, Goldstein RL, Cárdenas MG, Hatzi K, Rosen M, Shen H, Corcoran CM, Hamline MY, Gascoyne RD, Levine RL, Abdel-Wahab O, Licht JD, ... ... Melnick AM, et al. EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. Cancer Cell. 30: 197-213. PMID 27505670 DOI: 10.1016/J.Ccell.2016.07.006 | 0.58 | |||
| 2016 | Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, Oswald E, Hatzi K, Yang SN, Cohen J, Shaknovich R, Vanommeslaeghe K, Cheng H, Liang D, Cho HJ, ... ... Melnick AM, et al. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. The Journal of Clinical Investigation. PMID 27482887 DOI: 10.1172/Jci85795 | 0.367 | |||
| 2016 | Han D, Lu X, Shih AH, Nie J, You Q, Xu MM, Melnick AM, Levine RL, He C. A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations. Molecular Cell. PMID 27477909 DOI: 10.1016/J.Molcel.2016.06.028 | 0.337 | |||
| 2016 | Garrett-Bakelman FE, Melnick AM. Mutant IDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation. Epigenomics. PMID 27431380 DOI: 10.2217/epi-2016-0008 | 0.302 | |||
| 2016 | Li S, Garrett-Bakelman FE, Chung SS, Sanders MA, Hricik T, Rapaport F, Patel J, Dillon R, Vijay P, Brown AL, Perl AE, Cannon J, Bullinger L, Luger S, Becker M, ... ... Melnick AM, et al. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nature Medicine. PMID 27322744 DOI: 10.1038/Nm.4125 | 0.302 | |||
| 2016 | Robles EF, Mena-Varas M, Barrio L, Merino-Cortes SV, Balogh P, Du MQ, Akasaka T, Parker A, Roa S, Panizo C, Martin-Guerrero I, Siebert R, Segura V, Agirre X, Macri-Pellizeri L, ... ... Melnick AM, et al. Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics. Nature Communications. 7: 11889. PMID 27297662 DOI: 10.1038/ncomms11889 | 0.32 | |||
| 2016 | LaFave LM, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, Papalexi E, Keller MD, Hricik T, Konstantinoff K, Micol JB, Durham B, Knutson SK, Campbell JE, Blum G, ... ... Melnick A, et al. Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". Nature Medicine. 22: 578-579. PMID 27270773 DOI: 10.1038/Nm.4094 | 0.329 | |||
| 2016 | Li S, Mason C, Melnick A. Genetic and epigenetic heterogeneity in acute myeloid leukemia. Current Opinion in Genetics & Development. 36: 100-106. PMID 27162099 DOI: 10.1016/J.Gde.2016.03.011 | 0.383 | |||
| 2016 | Saba NS, Liu D, Herman SE, Underbayev C, Tian X, Behrend D, Weniger MA, Skarzynski M, Gyamfi J, Fontan L, Melnick A, Grant C, Roschewski M, Navarro A, Beà S, et al. Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma. Blood. PMID 27127301 DOI: 10.1182/Blood-2015-11-681460 | 0.394 | |||
| 2016 | Meyer SE, Qin T, Muench DE, Masuda K, Venkatasubramanian M, Orr E, Suarez L, Gore SD, Delwel R, Paietta E, Tallman MS, Fernandez H, Melnick A, Le Beau MM, Kogan S, et al. Dnmt3a haploinsufficiency transforms Flt3-ITD myeloproliferative disease into a rapid, spontaneous, and fully-penetrant acute myeloid leukemia. Cancer Discovery. PMID 27016502 DOI: 10.1158/2159-8290.Cd-16-0008 | 0.478 | |||
| 2016 | Shojaee S, Chan LN, Buchner M, Cazzaniga V, Cosgun KN, Geng H, Qiu YH, von Minden MD, Ernst T, Hochhaus A, Cazzaniga G, Melnick A, Kornblau SM, Graeber TG, Wu H, et al. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nature Medicine. PMID 26974310 DOI: 10.1038/Nm.4062 | 0.446 | |||
| 2016 | Kozloski GA, Jiang X, Bhatt S, Ruiz J, Vega F, Shaknovich R, Melnick A, Lossos IS. MiR-181a negatively regulates NF-κB signaling and affects activated B-cell like diffuse large B-cell lymphoma pathogenesis. Blood. PMID 26941399 DOI: 10.1182/Blood-2015-11-680462 | 0.323 | |||
| 2016 | Hurtz C, Chan LN, Ballabio E, Willman CL, Carroll WL, Armstrong SA, Ernst P, Melnick A, Milne T, Müschen M. Oncogenic Feedback Activation Between BCL6 and MLL Promotes Malignant Transformation in MLL-RearrangedAcute Lymphoblastic Leukemia Blood. 128: 907-907. DOI: 10.1182/Blood.V128.22.907.907 | 0.486 | |||
| 2016 | Vu LP, Prieto C, Amin E, Minuesa G, Chhangawala S, Vidal MJ, Krivtsov AV, Chou T, Barlowe T, Taggart J, Tivnan P, Deering RP, Gonen M, Figueroa ME, Paietta E, ... ... Melnick A, et al. RNA Binding Protein Syncrip Regulates the Leukemia Stem Cell Program Blood. 128: 739-739. DOI: 10.1182/Blood.V128.22.739.739 | 0.465 | |||
| 2016 | Ying H, Jiang Y, Ortega-Molina A, Geng H, McNally D, Wang L, Doane A, Agirre X, Ju H, Poloway D, Teater M, Parsa S, Ennishi D, Scott DW, Shaknovich R, ... Melnick A, et al. Crebbp Mutations Disrupt Dynamic Enhancer Acetylation in B-Cells, Enabling HDAC3 to Drive Lymphomagenesis Blood. 128: 735-735. DOI: 10.1182/Blood.V128.22.735.735 | 0.519 | |||
| 2016 | Béguelin W, Rivas MA, Fernández MTC, Melnick A. EZH2 Enables the Proliferation of Germinal Center B Cells and DLBCL through a Rb-E2F1 Positive Feedback Loop Involving Repression of CDKN1A Blood. 128: 734-734. DOI: 10.1182/Blood.V128.22.734.734 | 0.483 | |||
| 2016 | Rapaport F, de Massy MR, al Hinai A, Sanders MA, Hricik T, Sheridan C, Lee TC, Neelamraju Y, Patel J, Chung SS, Becker MW, Lewis ID, D'Andrea R, Bullinger L, Döhner K, ... ... Melnick A, et al. Changes of the Mutational Landscape in Relapsed Acute Myeloid Leukemia Blood. 128: 599-599. DOI: 10.1182/Blood.V128.22.599.599 | 0.384 | |||
| 2016 | Duy C, Teater M, Garrett-Bakelman FE, Carroll M, Melnick A. Acute Myeloid Leukemia Cells Resist Chemotherapy through a Reversible Senescence-like State Maintaining Repopulation Potential Blood. 128: 582-582. DOI: 10.1182/Blood.V128.22.582.582 | 0.435 | |||
| 2016 | Fachel AA, Muley AS, Meydan C, Agirre X, Cerchietti L, Melnick A, Richards KL. Targeting ß-Catenin Signaling in DLBCL with ICG-001 and PAM-1 Suppresses Cell Proliferation and Induces Apoptosis Blood. 128: 5382-5382. DOI: 10.1182/Blood.V128.22.5382.5382 | 0.366 | |||
| 2016 | Carrasco A, Ezponda T, Meydan C, Kulis M, Ordoñez R, Garate L, Segura V, Alignani D, Paiva B, Miguel JS, Subero JIM, Melnick A, Prosper F, Agirre X. Long Non-Coding RNAs Annotation and Their Involvement in Multiple Myeloma Blood. 128: 4420-4420. DOI: 10.1182/Blood.V128.22.4420.4420 | 0.421 | |||
| 2016 | Chan LN, Hurtz C, Xiao G, Shojaee S, Caeser R, Geng H, Melnick A, Müschen M. BCL6 Is Critical to Overcome Oncogene-Induced Senescence in RAS-Mediated B Cell Transformation Blood. 128: 438-438. DOI: 10.1182/Blood.V128.22.438.438 | 0.423 | |||
| 2016 | Lee J, Geng H, Chen Z, Klemm L, Cosgun KN, Xiao G, Masouleh B, Hurtz C, Parekh S, Kornblau SM, Melnick A, Abbas A, Paietta E, Müschen M. CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell Malignancies Blood. 128: 4088-4088. DOI: 10.1182/Blood.V128.22.4088.4088 | 0.405 | |||
| 2016 | Samaraweera SE, Garrett-Bakelman FE, Neelamraju Y, Perugini M, Casolari DA, Iarossi D, Bray SC, Sheridan C, Lee TC, Tiong IS, Danner S, Cummings N, Guzman ML, Roboz GJ, To LB, ... ... Melnick A, et al. Hypermethylation of GADD45A Defines a Methylation Profile Distinct to Mutant IDH1/2, and Correlates with More Aggressive AML Blood. 128: 2877-2877. DOI: 10.1182/Blood.V128.22.2877.2877 | 0.394 | |||
| 2016 | Duy C, Teater M, Garrett-Bakelman FE, Lee TC, Meydan C, Glass JL, Li M, Mohammad H, Smitheman K, Shih AH, Abdel-Wahab O, Paietta E, Tallman MS, Guzman ML, Kruger RG, ... Melnick A, et al. Cooperative Gene Repression By DNA Methylation and LSD1-Mediated Enhancer Inactivation in Acute Myeloid Leukemia Blood. 128: 1048-1048. DOI: 10.1182/Blood.V128.22.1048.1048 | 0.501 | |||
| 2016 | Dominguez MDP, Teater M, Redmond D, Cheng Z, Chaudhuri J, Elemento O, Melnick A, Shaknovich R. AICDA Introduces Epigenetic Plasticity in Germinal Center-Derived Lymphomas and Accelerates Lymphomagenesis Blood. 128: 1045-1045. DOI: 10.1182/Blood.V128.22.1045.1045 | 0.508 | |||
| 2016 | Marullo R, Ahn H, Cardenas M, Melnick A, Xue F, Cerchietti L. Abstract 1271: The transcription factor BCL6 is a rational target in non-small cell lung cancer (NSCLC) Cancer Research. 76: 1271-1271. DOI: 10.1158/1538-7445.Am2016-1271 | 0.474 | |||
| 2015 | Dupont T, Yang S, Patel J, Hatzi K, Malik A, Tam W, Martin P, Leonard J, Melnick A, Cerchietti L. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. Oncotarget. PMID 26657288 DOI: 10.18632/Oncotarget.6513 | 0.451 | |||
| 2015 | Zong H, Gozman A, Caldas-Lopes E, Taldone T, Sturgill E, Brennan S, Ochiana SO, Gomes-DaGama EM, Sen S, Rodina A, Koren J, Becker MW, Rudin CM, Melnick A, Levine RL, et al. A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species. Cell Reports. PMID 26628369 DOI: 10.1016/J.Celrep.2015.10.073 | 0.367 | |||
| 2015 | Culjkovic-Kraljacic B, Fernando TM, Marullo R, Calvo-Vidal N, Verma A, Yang S, Tabbò F, Gaudiano M, Zahreddine H, Goldstein RL, Patel J, Taldone T, Chiosis G, Ladetto M, Ghione P, ... ... Melnick A, et al. Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. Blood. PMID 26603836 DOI: 10.1182/Blood-2015-05-645069 | 0.412 | |||
| 2015 | Huang C, Melnick A. Mechanisms of action of BCL6 during germinal center B cell development. Science China. Life Sciences. PMID 26566802 DOI: 10.1007/S11427-015-4919-Z | 0.482 | |||
| 2015 | Goldstein RL, Yang SN, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K, Shaknovich R, Tam W, Leonard JP, Chiosis G, Cerchietti L, Melnick A. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. The Journal of Clinical Investigation. 2015. PMID 26529251 DOI: 10.1172/Jci80714 | 0.44 | |||
| 2015 | Verma A, Jiang Y, Du W, Fairchild L, Melnick A, Elemento O. Transcriptome sequencing reveals thousands of novel long non-coding RNAs in B cell lymphoma. Genome Medicine. 7: 110. PMID 26521025 DOI: 10.1182/Blood.V126.23.2427.2427 | 0.38 | |||
| 2015 | Viny AD, Ott CJ, Spitzer B, Rivas M, Meydan C, Papalexi E, Yelin D, Shank K, Reyes J, Chiu A, Romin Y, Boyko V, Thota S, Maciejewski JP, Melnick A, et al. Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. The Journal of Experimental Medicine. 212: 1819-32. PMID 26438361 DOI: 10.1182/Blood.V126.23.435.435 | 0.435 | |||
| 2015 | LaFave LM, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, Papalexi E, Keller MD, Hricik T, Konstantinoff K, Micol JB, Durham B, Knutson SK, Campbell JE, Blum G, ... ... Melnick A, et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nature Medicine. PMID 26437366 DOI: 10.1038/Nm.3947 | 0.439 | |||
| 2015 | Tian YF, Ahn H, Schneider RS, Yang SN, Roman-Gonzalez L, Melnick AM, Cerchietti L, Singh A. Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells. Biomaterials. 73: 110-119. PMID 26406451 DOI: 10.1016/j.biomaterials.2015.09.007 | 0.333 | |||
| 2015 | Ortega-Molina A, Boss IW, Canela A, Pan H, Jiang Y, Zhao C, Jiang M, Hu D, Agirre X, Niesvizky I, Lee JE, Chen HT, Ennishi D, Scott DW, Mottok A, ... ... Melnick AM, et al. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nature Medicine. PMID 26366710 DOI: 10.1038/Nm.3943 | 0.415 | |||
| 2015 | Dominguez PM, Teater M, Chambwe N, Kormaksson M, Redmond D, Ishii J, Vuong B, Chaudhuri J, Melnick A, Vasanthakumar A, Godley LA, Papavasiliou FN, Elemento O, Shaknovich R. DNA Methylation Dynamics of Germinal Center B Cells Are Mediated by AID. Cell Reports. 12: 2086-98. PMID 26365193 DOI: 10.1016/J.Celrep.2015.08.036 | 0.453 | |||
| 2015 | Noh KM, Wang H, Kim HR, Wenderski W, Fang F, Li CH, Dewell S, Hughes SH, Melnick AM, Patel DJ, Li H, Allis CD. Engineering of a Histone-Recognition Domain in Dnmt3a Alters the Epigenetic Landscape and Phenotypic Features of Mouse ESCs. Molecular Cell. 59: 89-103. PMID 26073541 DOI: 10.1016/J.Molcel.2015.05.017 | 0.317 | |||
| 2015 | Shojaee S, Caeser R, Buchner M, Park E, Swaminathan S, Hurtz C, Geng H, Chan LN, Klemm L, Hofmann WK, Qiu YH, Zhang N, Coombes KR, Paietta E, Molkentin J, ... ... Melnick A, et al. Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. Cancer Cell. 28: 114-28. PMID 26073130 DOI: 10.1016/J.Ccell.2015.05.008 | 0.46 | |||
| 2015 | Shih AH, Jiang Y, Meydan C, Shank K, Pandey S, Barreyro L, Antony-Debre I, Viale A, Socci N, Sun Y, Robertson A, Cavatore M, de Stanchina E, Hricik T, Rapaport F, ... ... Melnick A, et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell. 27: 502-15. PMID 25873173 DOI: 10.1016/J.Ccell.2015.03.009 | 0.446 | |||
| 2015 | Hatzi K, Nance JP, Kroenke MA, Bothwell M, Haddad EK, Melnick A, Crotty S. BCL6 orchestrates Tfh cell differentiation via multiple distinct mechanisms. The Journal of Experimental Medicine. 212: 539-53. PMID 25824819 DOI: 10.1084/Jem.20141380 | 0.456 | |||
| 2015 | Jiang Y, Melnick A. The epigenetic basis of diffuse large B-cell lymphoma. Seminars in Hematology. 52: 86-96. PMID 25805588 DOI: 10.1053/J.Seminhematol.2015.01.003 | 0.47 | |||
| 2015 | Chen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L, Titz B, Graeber TG, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Willman CL, Melnick A, et al. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature. 521: 357-61. PMID 25799995 DOI: 10.1038/Nature14231 | 0.433 | |||
| 2015 | Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, ... ... Melnick A, et al. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell. 27: 409-25. PMID 25759025 DOI: 10.1016/J.Ccell.2015.02.003 | 0.396 | |||
| 2015 | Buchner M, Park E, Geng H, Klemm L, Flach J, Passegué E, Schjerven H, Melnick A, Paietta E, Kopanja D, Raychaudhuri P, Müschen M. Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia. Nature Communications. 6: 6471. PMID 25753524 DOI: 10.1038/Ncomms7471 | 0.478 | |||
| 2015 | Park SM, Gönen M, Vu L, Minuesa G, Tivnan P, Barlowe TS, Taggart J, Lu Y, Deering RP, Hacohen N, Figueroa ME, Paietta E, Fernandez HF, Tallman MS, Melnick A, et al. Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. The Journal of Clinical Investigation. 125: 1286-98. PMID 25664853 DOI: 10.1172/Jci78440 | 0.41 | |||
| 2015 | Chen L, Chen W, Mysliwski M, Serio J, Ropa J, Abulwerdi FA, Chan RJ, Patel JP, Tallman MS, Paietta E, Melnick A, Levine RL, Abdel-Wahab O, Nikolovska-Coleska Z, Muntean AG. Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition. Leukemia. 29: 1290-300. PMID 25650089 DOI: 10.1038/Leu.2015.18 | 0.475 | |||
| 2015 | Agirre X, Castellano G, Pascual M, Heath S, Kulis M, Segura V, Bergmann A, Esteve A, Merkel A, Raineri E, Agueda L, Blanc J, Richardson D, Clarke L, Datta A, ... ... Melnick A, et al. Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. Genome Research. 25: 478-87. PMID 25644835 DOI: 10.1016/J.Clml.2015.07.243 | 0.465 | |||
| 2015 | Kuo PY, Leshchenko VV, Fazzari MJ, Perumal D, Gellen T, He T, Iqbal J, Baumgartner-Wennerholm S, Nygren L, Zhang F, Zhang W, Suh KS, Goy A, Yang DT, Chan WC, ... Melnick AM, et al. High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma. Oncogene. 34: 1231-40. PMID 24681958 DOI: 10.1038/Onc.2014.44 | 0.361 | |||
| 2015 | Walker SR, Liu S, Xiang M, Nicolais M, Hatzi K, Giannopoulou E, Elemento O, Cerchietti L, Melnick A, Frank DA. The transcriptional modulator BCL6 as a molecular target for breast cancer therapy. Oncogene. 34: 1073-82. PMID 24662818 DOI: 10.1038/Onc.2014.61 | 0.383 | |||
| 2015 | LaFave LM, Béguelin W, Koche R, Teater M, Papalexi E, Spitzer B, Knutson S, Campbell J, Keilhack H, Thomas PM, Kelleher NL, Abdel-Wahab O, Melnick AM, Armstrong SA, Levine RL. BAP1 Loss Results in EZH2-Dependent Transformation in Myelodysplastic Syndromes Blood. 126: 713-713. DOI: 10.1182/Blood.V126.23.713.713 | 0.347 | |||
| 2015 | Li Q, Hurtz C, Shojaee S, Chen Z, Geng H, Xiao G, Loh ML, Ye BH, Melnick A, Muschen M. Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic Leukemia Blood. 126: 556-556. DOI: 10.1182/Blood.V126.23.556.556 | 0.435 | |||
| 2015 | Béguelin W, Teater M, Corcoran C, Hamline M, Gascoyne RD, Levine RL, Abdel-Wahab O, Shaknovich R, Elemento O, Bardwell VJ, Melnick A. A Chromatin Reader That Acts As a Key to Lock in and Coordinate Recruitment of Transcription Factors and a Novel Polycomb Complex to Bivalent Chromatin Thus Driving Formation of Germinal Centers and B-Cell Lymphomas Blood. 126: 434-434. DOI: 10.1182/Blood.V126.23.434.434 | 0.535 | |||
| 2015 | Chen Z, Geng H, Lowell CA, Weiss A, Hunger SP, Melnick A, Muschen M. Targeted Activation of B Cell Autoimmunity Checkpoints in Acute Lymphoblastic Leukemia Blood. 126: 3716-3716. DOI: 10.1182/Blood.V126.23.3716.3716 | 0.436 | |||
| 2015 | Garrett-Bakelman FE, Li S, Chung SS, Hricik T, Franck R, Patel J, Dillon R, Vijay P, Brown AL, Perl AE, Cannon BJ, Sanders MA, Valk PJM, Bullinger L, Luger S, ... ... Melnick A, et al. Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia Blood. 126: 306-306. DOI: 10.1182/Blood.V126.23.306.306 | 0.435 | |||
| 2015 | Lee J, Chen Z, Geng H, Xiao G, PARK E, Parekh S, Kornblau SM, Melnick A, Abbas A, Paietta E, Muschen M. CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia Blood. 126: 1434-1434. DOI: 10.1182/Blood.V126.23.1434.1434 | 0.364 | |||
| 2015 | Rapaport F, Patel J, He J, Brennan TA, Nahas M, Balassubramanian S, Otto G, Lipson D, Stephens P, Miller VA, Racevskis J, Litzow MR, Wiernik PH, Goldstone AH, Luger S, ... ... Melnick A, et al. Integrated DNA/RNA Profiling for Somatic Alterations in Adult B-Cell ALL Blood. 126: 1422-1422. DOI: 10.1182/Blood.V126.23.1422.1422 | 0.442 | |||
| 2015 | Kraljacic-Culkjovic B, Fernando T, Goldstein R, Mctavish C, Patel J, Yang S, Tabbo F, Melnick A, Inghirami G, Borden KL, Cerchietti L. Abstract B12: EIF4E deregulation drives simultaneous expression of B-cell lymphoma oncogenes. Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Hemmal14-B12 | 0.485 | |||
| 2015 | Fontan L, Yang C, Shinglot H, Kabaleeswaran V, Laurent V, Osborne M, Beltran E, Rosen M, Shaknovich R, Yang SN, Gascoyne RD, Cerchietti L, MArtinez-Climent JA, Glickman JF, Borden K, ... ... Melnick A, et al. Abstract A19: MALT1 inhibition as an anchor for combinatorial therapy of ABC-DLBCL. Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Hemmal14-A19 | 0.453 | |||
| 2015 | Ortega-Molina A, Boss I, Pan H, Jiang Y, Hu D, Gao X, Shaknovich R, Shilatifard A, Melnick AM, Wendel H. Abstract LB-064: Characterization of the tumor suppressor function of the lysine-specific methyltransferase KMT2D in follicular lymphoma Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-064 | 0.384 | |||
| 2015 | Rodina AA, Taldone T, Kang Y, Patel P, Koren J, Yan P, Gomes ED, Yang C, Patel M, Shrestha L, Ochiana S, Maharaj R, Gozman A, Cox M, Erdjument-Bromage H, ... ... Melnick A, et al. Abstract 1733: Development of chemical tools to study the endogenous Hsp70 interactome in malignant cells Cancer Research. 75: 1733-1733. DOI: 10.1158/1538-7445.Am2015-1733 | 0.369 | |||
| 2015 | McConnell M, Fabre M, Jones N, Rowe M, Hung N, Melnick A, Slatter T. Cbio-24Glioblastoma Multiforme Cells Are Addicted To The Oncogenic Survival Factor Bcl6 Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov209.24 | 0.454 | |||
| 2014 | Rampal R, Alkalin A, Madzo J, Vasanthakumar A, Pronier E, Patel J, Li Y, Ahn J, Abdel-Wahab O, Shih A, Lu C, Ward PS, Tsai JJ, Hricik T, Tosello V, ... ... Melnick A, et al. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Reports. 9: 1841-55. PMID 25482556 DOI: 10.1016/J.Celrep.2014.11.004 | 0.562 | |||
| 2014 | Patel RG, Purwada A, Cerchietti L, Inghirami G, Melnick A, Gaharwar AK, Singh A. Microscale Bioadhesive Hydrogel Arrays for Cell Engineering Applications. Cellular and Molecular Bioengineering. 7: 394-408. PMID 25328548 DOI: 10.1007/S12195-014-0353-8 | 0.349 | |||
| 2014 | Li S, Garrett-Bakelman F, Perl AE, Luger SM, Zhang C, To BL, Lewis ID, Brown AL, D'Andrea RJ, Ross ME, Levine R, Carroll M, Melnick A, Mason CE. Dynamic evolution of clonal epialleles revealed by methclone. Genome Biology. 15: 472. PMID 25260792 DOI: 10.1186/S13059-014-0472-5 | 0.326 | |||
| 2014 | Huang C, Gonzalez DG, Cote CM, Jiang Y, Hatzi K, Teater M, Dai K, Hla T, Haberman AM, Melnick A. The BCL6 RD2 domain governs commitment of activated B cells to form germinal centers. Cell Reports. 8: 1497-508. PMID 25176650 DOI: 10.1016/J.Celrep.2014.07.059 | 0.417 | |||
| 2014 | Jiang Y, Redmond D, Nie K, Eng KW, Clozel T, Martin P, Tan LH, Melnick AM, Tam W, Elemento O. Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas. Genome Biology. 15: 432. PMID 25123191 DOI: 10.1186/s13059-014-0432-0 | 0.31 | |||
| 2014 | Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla KN. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget. 5: 5637-50. PMID 25026298 DOI: 10.18632/Oncotarget.2154 | 0.306 | |||
| 2014 | Rodina A, Taldone T, Kang Y, Patel PD, Koren J, Yan P, DaGama Gomes EM, Yang C, Patel MR, Shrestha L, Ochiana SO, Santarossa C, Maharaj R, Gozman A, Cox MB, ... ... Melnick A, et al. Affinity purification probes of potential use to investigate the endogenous Hsp70 interactome in cancer. Acs Chemical Biology. 9: 1698-705. PMID 24934503 DOI: 10.1021/Cb500256U | 0.33 | |||
| 2014 | Green MR, Vicente-Dueñas C, Romero-Camarero I, Long Liu C, Dai B, González-Herrero I, García-Ramírez I, Alonso-Escudero E, Iqbal J, Chan WC, Campos-Sanchez E, Orfao A, Pintado B, Flores T, Blanco O, ... ... Melnick A, et al. Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. Nature Communications. 5: 3904. PMID 24887457 DOI: 10.1038/Ncomms4904 | 0.51 | |||
| 2014 | Chung SS, Kim E, Park JH, Chung YR, Lito P, Teruya-Feldstein J, Hu W, Beguelin W, Monette S, Duy C, Rampal R, Telis L, Patel M, Kim MK, Huberman K, ... ... Melnick AM, et al. Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Science Translational Medicine. 6: 238ra71. PMID 24871132 DOI: 10.1126/Scitranslmed.3008004 | 0.324 | |||
| 2014 | Kharabi Masouleh B, Geng H, Hurtz C, Chan LN, Logan AC, Chang MS, Huang C, Swaminathan S, Sun H, Paietta E, Melnick AM, Koeffler P, Müschen M. Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 111: E2219-28. PMID 24821775 DOI: 10.1073/Pnas.1400958111 | 0.374 | |||
| 2014 | Kemp CJ, Moore JM, Moser R, Bernard B, Teater M, Smith LE, Rabaia NA, Gurley KE, Guinney J, Busch SE, Shaknovich R, Lobanenkov VV, Liggitt D, Shmulevich I, Melnick A, et al. CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancer. Cell Reports. 7: 1020-9. PMID 24794443 DOI: 10.1016/J.Celrep.2014.04.004 | 0.375 | |||
| 2014 | Hatzi K, Melnick A. Breaking bad in the germinal center: How deregulation of BCL6 contributes to lymphomagenesis Trends in Molecular Medicine. 20: 343-352. PMID 24698494 DOI: 10.1016/J.Molmed.2014.03.001 | 0.486 | |||
| 2014 | Taskesen E, Havermans M, van Lom K, Sanders MA, van Norden Y, Bindels E, Hoogenboezem R, Reinders MJ, Figueroa ME, Valk PJ, Löwenberg B, Melnick A, Delwel R. Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling. Blood. 123: 3327-35. PMID 24668493 DOI: 10.1182/Blood-2013-07-512855 | 0.419 | |||
| 2014 | Prebet T, Sun Z, Figueroa ME, Ketterling R, Melnick A, Greenberg PL, Herman J, Juckett M, Smith MR, Malick L, Paietta E, Czader M, Litzow M, Gabrilove J, Erba HP, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1242-8. PMID 24663049 DOI: 10.1200/Jco.2013.50.3102 | 0.318 | |||
| 2014 | Fiskus W, Saba N, Shen M, Ghias M, Liu J, Gupta SD, Chauhan L, Rao R, Gunewardena S, Schorno K, Austin CP, Maddocks K, Byrd J, Melnick A, Huang P, et al. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Research. 74: 2520-32. PMID 24599128 DOI: 10.1158/0008-5472.Can-13-2033 | 0.395 | |||
| 2014 | Bartholdy B, Christopeit M, Will B, Mo Y, Barreyro L, Yu Y, Bhagat TD, Okoye-Okafor UC, Todorova TI, Greally JM, Levine RL, Melnick A, Verma A, Steidl U. HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia. The Journal of Clinical Investigation. 124: 1158-67. PMID 24487588 DOI: 10.1172/Jci71264 | 0.439 | |||
| 2014 | Chambwe N, Kormaksson M, Geng H, De S, Michor F, Johnson NA, Morin RD, Scott DW, Godley LA, Gascoyne RD, Melnick A, Campagne F, Shaknovich R. Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood. 123: 1699-708. PMID 24385541 DOI: 10.1182/Blood-2013-07-509885 | 0.427 | |||
| 2014 | Huang C, Geng H, Boss I, Wang L, Melnick A. Cooperative transcriptional repression by BCL6 and BACH2 in germinal center B-cell differentiation Blood. 123: 1012-1020. PMID 24277074 DOI: 10.1182/Blood-2013-07-518605 | 0.499 | |||
| 2014 | Oyer JA, Huang X, Zheng Y, Shim J, Ezponda T, Carpenter Z, Allegretta M, Okot-Kotber CI, Patel JP, Melnick A, Levine RL, Ferrando A, Mackerell AD, Kelleher NL, Licht JD, et al. Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies. Leukemia. 28: 198-201. PMID 23823660 DOI: 10.1038/Leu.2013.204 | 0.548 | |||
| 2014 | Park SM, Gönen M, Vu LP, Minuesa G, Tivnan P, Barlowe T, Taggart J, Lu Y, Deering RP, Hacohen N, Figueroa M, Paietta EM, Tallman MS, Melnick AM, Levine RL, et al. Msi2 Maintains the MLL Leukemia Stem Cell Regulatory Program Blood. 124: 836-836. DOI: 10.1182/Blood.V124.21.836.836 | 0.398 | |||
| 2014 | Chen Z, Shojaee S, Geng H, Lee J, Buchner M, Klemm L, Lowell CA, Paietta E, Willman CL, Carroll WL, Melnick A, Jung JU, Jumaa H, Coligan JE, Bolland S, et al. Harnessing Negative B Cell Selection to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia Blood. 124: 792-792. DOI: 10.1182/Blood.V124.21.792.792 | 0.421 | |||
| 2014 | Geng H, Lee J, Chen Z, Kharabi Masouleh B, Hurtz C, Park E, Xiao G, Parekh S, Kornblau SM, Melnick A, Paietta E, Muschen M. IL2RA (CD25) Recruits Inhibitory Phosphatases to the Cell Membrane and Mediates Negative Feedback Control of STAT5 Signaling in Acute Lymphoblastic Leukemia Blood. 124: 788-788. DOI: 10.1182/Blood.V124.21.788.788 | 0.37 | |||
| 2014 | Seyedmehdi S, Chen Z, Buchner M, Hurtz C, Geng H, Schjerven H, Chan LN, Koeffler P, Willman CL, Hunger S, Dovat S, Paietta E, Hofmann W, Melnick AM, Alexander WS, et al. Erk and Stat5 Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia Blood. 124: 787-787. DOI: 10.1182/Blood.V124.21.787.787 | 0.348 | |||
| 2014 | Perugini M, Samaraweera SE, Brown AL, Cummings N, Danner S, Tiong IS, Garrett-Bakelman FE, Carroll MP, Becker MW, Chung SS, Park CY, Mason CE, Guzman ML, Levine RL, Melnick AM, et al. The Significance of GADD45A Promoter DNA Hypermethylation in AML: Association with IDH1/2 and TET2 Mutation Blood. 124: 69-69. DOI: 10.1182/Blood.V124.21.69.69 | 0.334 | |||
| 2014 | Fernando TM, Yang SN, Huang C, Chiosis G, Cerchietti L, Melnick AM. BCL6 Mediates a Stress Tolerance Phenotype through Its BTB Domain Blood. 124: 567-567. DOI: 10.1182/Blood.V124.21.567.567 | 0.37 | |||
| 2014 | Flynn RP, Goodman K, Qi J, Jing D, Panoskaltsis-Mortari A, Yi Z, Dong C, Liu X, MacDonald KPA, Hill GR, Serody JS, Murphy WJ, Luznik L, Maillard I, Koreth J, ... Melnick AM, et al. Targeting BCL6 and Germinal Centers (GCs) in Chronic Graft-Versus-Host Disease (cGVHD) Using Direct and Epigenomic Therapies Blood. 124: 535-535. DOI: 10.1182/Blood.V124.21.535.535 | 0.377 | |||
| 2014 | Park E, Swaminathan S, Sadiyah MF, Igarashi K, Melnick A, Muschen M. BACH2 promotes Lineage-Specific Fate Decisions in BCR-ABL1-Driven Leukemia Blood. 124: 513-513. DOI: 10.1182/Blood.V124.21.513.513 | 0.455 | |||
| 2014 | Shih AH, Shank KR, Meydan C, Intlekofer AM, Ward P, Thompson CB, Melnick AM, Travins J, Straley K, Gliser C, Yen K, Levine RL. AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo Blood. 124: 437-437. DOI: 10.1182/Blood.V124.21.437.437 | 0.319 | |||
| 2014 | Hatzi K, Nance JP, Kroenke M, Haddad EK, Melnick AM, Crotty S. BCL6 Orchestrates Tfh Differentiation Via Multiple Distinct Mechanisms Blood. 124: 4137-4137. DOI: 10.1182/Blood.V124.21.4137.4137 | 0.362 | |||
| 2014 | Hurtz C, Geng H, Xiao G, Loh ML, Ye BH, Melnick A, Muschen M. BCL6 Enables RAS-Mediated Pre-B Cell Transformation in Childhood Acute Lymphoblastic Leukemia Blood. 124: 3570-3570. DOI: 10.1182/Blood.V124.21.3570.3570 | 0.463 | |||
| 2014 | Chen L, Chen W, Mysliwski M, Serio J, Ropa J, Abulwerdi F, Chan RJ, Patel JP, Tallman MS, Paietta EM, Melnick AM, Levine RL, Abdel-Wahab O, Nikolovska-Coleska Z, Muntean AG. Hyperactive Ptpn11 Mutations Alters Leukemic Stem Cell Frequency through Mcl-1 Overexpression Blood. 124: 3565-3565. DOI: 10.1182/Blood.V124.21.3565.3565 | 0.339 | |||
| 2014 | Geng H, Hurtz C, Baumjohann D, Chen Z, Chen W, Ballabio E, Xiao G, Lee J, Deucher A, Qi Z, Huang C, Nahar R, Kweon S, Shojaee S, Chan LN, ... Melnick A, et al. Self-Enforcing Feedback Activation Between BCL6 and Tonic Pre-B Cell Receptor Signaling in Acute Lymphoblastic Leukemia Blood. 124: 284-284. DOI: 10.1182/Blood.V124.21.284.284 | 0.472 | |||
| 2014 | Shojaee S, Cazzaniga V, Schjerven H, Buchner M, Hurtz C, Geng H, Hochhaus A, Cazzaniga G, Melnick AM, Kornblau SM, Graeber TG, Muschen M. PTEN Is Essential for Normal Cytokine Signaling and Oncogenic Transformation of Pre-B Cells Blood. 124: 262-262. DOI: 10.1182/Blood.V124.21.262.262 | 0.385 | |||
| 2014 | Agirre X, Castellano G, Pascual M, Kulis M, Segura V, Bergmann A, Esteve A, Merkel A, Raineri E, Agueda L, Blanc J, Richardson D, Clarke L, Russiñol N, Queirós AC, ... Melnick AM, et al. Whole-genome epigenomic analysis in multiple myeloma reveals DNA hypermethylation of b-cell specific enhancers Blood. 124: 2032-2032. DOI: 10.1182/Blood.V124.21.2032.2032 | 0.364 | |||
| 2014 | Calvo-Vidal N, Patel J, Krumsiek J, Dupont T, Goldstein R, Yang SN, Melnick A, Chiosis G, Cerchietti L. Hsp90 at the Hub of Metabolic Homeostasis in Malignant B Cells Blood. 124: 1764-1764. DOI: 10.1182/Blood.V124.21.1764.1764 | 0.384 | |||
| 2014 | Beguelin W, Teater M, Popovic R, Jiang Y, Cerchietti L, Shaknovich R, Gascoyne R, Levine R, Abdel-Wahab O, Licht J, Elemento O, Melnick AM. Abstract SY09-03: How deregulation of histone methyltransferases drive malignant transformation of B-cells Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Sy09-03 | 0.626 | |||
| 2014 | Cardenas MG, Teater MR, Calvo-Vidal N, Yang SN, Glickman JF, Melnick A, Cerchietti L. Abstract 4232: Small molecule phenotypic targeting of aggressive B-cell lymphomas Cancer Research. 74: 4232-4232. DOI: 10.1158/1538-7445.Am2014-4232 | 0.45 | |||
| 2014 | Kim E, Chung SS, Park JH, Chung YR, Lito P, Feldstein J, Hu W, Beguilin W, Monette S, Duy C, Rampal R, Telis L, Patel M, Kim MK, Melnick AM, et al. Abstract 3140: Context specific effects of the BRAFV600E mutation on hematopoiesis identifies novel models of BRAF mutant hematopoietic disorders Cancer Research. 74: 3140-3140. DOI: 10.1158/1538-7445.Am2014-3140 | 0.327 | |||
| 2014 | Fontan L, Yang C, Kabaleeswaran V, Volpon L, Osborne M, Beltran E, Rosen M, Shaknovich R, Yang SN, Gascoyne RD, Cerchietti L, Martinez-Climent JA, Glickman JF, Borden K, Wu H, ... Melnick A, et al. Abstract 2693: Harnessing MALT1 inhibition for rational combinatorial therapy of ABC-DLBCL Cancer Research. 74: 2693-2693. DOI: 10.1158/1538-7445.Am2014-2693 | 0.419 | |||
| 2014 | Will B, Todorova T, Verma A, Steidl U, Melnick A. Regulation of hematopoietic stem cell fate by special at-rich sequence binding protein 1 Experimental Hematology. 42. DOI: 10.1016/J.Exphem.2014.07.251 | 0.408 | |||
| 2013 | Vu LP, Perna F, Wang L, Voza F, Figueroa ME, Tempst P, Erdjument-Bromage H, Gao R, Chen S, Paietta E, Deblasio T, Melnick A, Liu Y, Zhao X, Nimer SD. PRMT4 blocks myeloid differentiation by assembling a methyl-RUNX1-dependent repressor complex. Cell Reports. 5: 1625-38. PMID 24332853 DOI: 10.1016/J.Celrep.2013.11.025 | 0.447 | |||
| 2013 | Di Ruscio A, Ebralidze AK, Benoukraf T, Amabile G, Goff LA, Terragni J, Figueroa ME, De Figueiredo Pontes LL, Alberich-Jorda M, Zhang P, Wu M, D'Alò F, Melnick A, Leone G, Ebralidze KK, et al. DNMT1-interacting RNAs block gene-specific DNA methylation. Nature. 503: 371-6. PMID 24107992 DOI: 10.1038/Nature12598 | 0.39 | |||
| 2013 | Qiao Q, Yang C, Zheng C, Fontán L, David L, Yu X, Bracken C, Rosen M, Melnick A, Egelman EH, Wu H. Structural architecture of the CARMA1/Bcl10/MALT1 signalosome: nucleation-induced filamentous assembly. Molecular Cell. 51: 766-79. PMID 24074955 DOI: 10.1016/J.Molcel.2013.08.032 | 0.327 | |||
| 2013 | Lu C, Venneti S, Akalin A, Fang F, Ward PS, Dematteo RG, Intlekofer AM, Chen C, Ye J, Hameed M, Nafa K, Agaram NP, Cross JR, Khanin R, Mason CE, ... ... Melnick A, et al. Induction of sarcomas by mutant IDH2. Genes & Development. 27: 1986-98. PMID 24065766 DOI: 10.1101/Gad.226753.113 | 0.432 | |||
| 2013 | Lai AY, Mav D, Shah R, Grimm SA, Phadke D, Hatzi K, Melnick A, Geigerman C, Sobol SE, Jaye DL, Wade PA. DNA methylation profiling in human B cells reveals immune regulatory elements and epigenetic plasticity at Alu elements during B-cell activation. Genome Research. 23: 2030-41. PMID 24013550 DOI: 10.1101/Gr.155473.113 | 0.402 | |||
| 2013 | Fontán L, Melnick A. Molecular pathways: Targeting MALT1 paracaspase activity in lymphoma Clinical Cancer Research. 19: 6662-6668. PMID 24004675 DOI: 10.1158/1078-0432.Ccr-12-3869 | 0.433 | |||
| 2013 | Cerchietti L, Melnick A. Targeting BCL6 in diffuse large B-cell lymphoma: What does this mean for the future treatment? Expert Review of Hematology. 6: 343-345. PMID 23991920 DOI: 10.1586/17474086.2013.826928 | 0.44 | |||
| 2013 | Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW, Wyman S, Leser M, Shaknovich R, Chadburn A, Tabbo F, ... ... Melnick A, et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discovery. 3: 1002-19. PMID 23955273 DOI: 10.1158/2159-8290.Cd-13-0117 | 0.444 | |||
| 2013 | Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T, Erdjument-Bromage H, Chomet M, Blasberg R, Melnick A, Cerchietti L, Chiosis G, Wang YL, Cesarman E. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. Blood. 122: 2837-47. PMID 23943653 DOI: 10.1182/Blood-2013-01-479972 | 0.394 | |||
| 2013 | Figueroa ME, Chen SC, Andersson AK, Phillips LA, Li Y, Sotzen J, Kundu M, Downing JR, Melnick A, Mullighan CG. Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia. The Journal of Clinical Investigation. 123: 3099-111. PMID 23921123 DOI: 10.1172/Jci66203 | 0.43 | |||
| 2013 | Hatzi K, Jiang Y, Huang C, Garrett-Bakelman F, Gearhart MD, Giannopoulou EG, Zumbo P, Kirouac K, Bhaskara S, Polo JM, Kormaksson M, MacKerell AD, Xue F, Mason CE, Hiebert SW, ... ... Melnick A, et al. A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters. Cell Reports. 4: 578-88. PMID 23911289 DOI: 10.1016/J.Celrep.2013.06.016 | 0.491 | |||
| 2013 | Swaminathan S, Huang C, Geng H, Chen Z, Harvey R, Kang H, Ng C, Titz B, Hurtz C, Sadiyah MF, Nowak D, Thoennissen GB, Rand V, Graeber TG, Koeffler HP, ... ... Melnick A, et al. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nature Medicine. 19: 1014-22. PMID 23852341 DOI: 10.1038/Nm.3247 | 0.495 | |||
| 2013 | Santini V, Melnick A, Maciejewski JP, Duprez E, Nervi C, Cocco L, Ford KG, Mufti G. Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. Critical Reviews in Oncology/Hematology. 88: 231-45. PMID 23838480 DOI: 10.1016/J.Critrevonc.2013.06.004 | 0.31 | |||
| 2013 | Sun XJ, Wang Z, Wang L, Jiang Y, Kost N, Soong TD, Chen WY, Tang Z, Nakadai T, Elemento O, Fischle W, Melnick A, Patel DJ, Nimer SD, Roeder RG. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis. Nature. 500: 93-7. PMID 23812588 DOI: 10.1038/Nature12287 | 0.444 | |||
| 2013 | Bertolo C, Roa S, Sagardoy A, Mena-Varas M, Robles EF, Martinez-Ferrandis JI, Sagaert X, Tousseyn T, Orta A, Lossos IS, Amar S, Natkunam Y, Briones J, Melnick A, Malumbres R, et al. LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomas. British Journal of Haematology. 162: 621-30. PMID 23795761 DOI: 10.1111/Bjh.12440 | 0.503 | |||
| 2013 | Bunting KL, Melnick AM. New effector functions and regulatory mechanisms of BCL6 in normal and malignant lymphocytes Current Opinion in Immunology. 25: 339-346. PMID 23725655 DOI: 10.1016/j.coi.2013.05.003 | 0.318 | |||
| 2013 | Béguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SN, Wang L, Ezponda T, Martinez-Garcia E, Zhang H, Zheng Y, Verma SK, McCabe MT, ... ... Melnick AM, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 23: 677-92. PMID 23680150 DOI: 10.1016/J.Ccr.2013.04.011 | 0.606 | |||
| 2013 | Fontan L, Melnick A. Discovering what makes STAT signaling TYK in T-ALL Cancer Discovery. 3: 494-496. PMID 23658297 DOI: 10.1158/2159-8290.Cd-13-0123 | 0.309 | |||
| 2013 | Ruan J, Luo M, Wang C, Fan L, Yang SN, Cardenas M, Geng H, Leonard JP, Melnick A, Cerchietti L, Hajjar KA. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood. 121: 5192-202. PMID 23632889 DOI: 10.1182/Blood-2013-03-490763 | 0.381 | |||
| 2013 | Sagardoy A, Martinez-Ferrandis JI, Roa S, Bunting KL, Aznar MA, Elemento O, Shaknovich R, Fontán L, Fresquet V, Perez-Roger I, Robles EF, De Smedt L, Sagaert X, Melnick A, Martinez-Climent JA. Downregulation of FOXP1 is required during germinal center B-cell function. Blood. 121: 4311-20. PMID 23580662 DOI: 10.1182/Blood-2012-10-462846 | 0.475 | |||
| 2013 | Will B, Vogler TO, Bartholdy B, Garrett-Bakelman F, Mayer J, Barreyro L, Pandolfi A, Todorova TI, Okoye-Okafor UC, Stanley RF, Bhagat TD, Verma A, Figueroa ME, Melnick A, Roth M, et al. Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment. Nature Immunology. 14: 437-45. PMID 23563689 DOI: 10.1038/Ni.2572 | 0.377 | |||
| 2013 | Lu Z, Tsai AG, Akasaka T, Ohno H, Jiang Y, Melnick AM, Greisman HA, Lieber MR. BCL6 breaks occur at different AID sequence motifs in Ig-BCL6 and non-Ig-BCL6 rearrangements. Blood. 121: 4551-4. PMID 23476051 DOI: 10.1182/Blood-2012-10-464958 | 0.301 | |||
| 2013 | Huang C, Hatzi K, Melnick A. Lineage-specific functions of Bcl-6 in immunity and inflammation are mediated by distinct biochemical mechanisms Nature Immunology. 14: 380-388. PMID 23455674 DOI: 10.1038/Ni.2543 | 0.405 | |||
| 2013 | Wilkinson AC, Ballabio E, Geng H, North P, Tapia M, Kerry J, Biswas D, Roeder RG, Allis CD, Melnick A, de Bruijn MF, Milne TA. RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction. Cell Reports. 3: 116-27. PMID 23352661 DOI: 10.1016/J.Celrep.2012.12.016 | 0.418 | |||
| 2013 | De S, Shaknovich R, Riester M, Elemento O, Geng H, Kormaksson M, Jiang Y, Woolcock B, Johnson N, Polo JM, Cerchietti L, Gascoyne RD, Melnick A, Michor F. Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. Plos Genetics. 9: e1003137. PMID 23326238 DOI: 10.1371/Journal.Pgen.1003137 | 0.486 | |||
| 2013 | Krivtsov AV, Figueroa ME, Sinha AU, Stubbs MC, Feng Z, Valk PJM, Delwel R, Döhner K, Bullinger L, Kung AL, Melnick AM, Armstrong SA. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML Leukemia. 27: 852-860. PMID 23235717 DOI: 10.1038/Leu.2012.363 | 0.35 | |||
| 2013 | Ramezani-Rad P, Geng H, Hurtz C, Chan LN, Chen Z, Jumaa H, Melnick A, Paietta E, Carroll WL, Willman CL, Lefebvre V, Müschen M. SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. Blood. 121: 148-55. PMID 23152540 DOI: 10.1182/Blood-2012-05-428938 | 0.463 | |||
| 2013 | Nischal S, Bhattacharyya S, Christopeit M, Yu Y, Zhou L, Bhagat TD, Sohal D, Will B, Mo Y, Suzuki M, Pardanani A, McDevitt M, Maciejewski JP, Melnick AM, Greally JM, et al. Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms. Cancer Research. 73: 1076-85. PMID 23066032 DOI: 10.1158/0008-5472.Can-12-0735 | 0.344 | |||
| 2013 | Park-Min KH, Lee EY, Moskowitz NK, Lim E, Lee SK, Lorenzo JA, Huang C, Melnick AM, Purdue PE, Goldring SR, Ivashkiv LB. Negative regulation of osteoclast precursor differentiation by CD11b and β2 integrin-B-cell lymphoma 6 signaling. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 28: 135-49. PMID 22893614 DOI: 10.1002/Jbmr.1739 | 0.3 | |||
| 2013 | Masouleh BK, Geng H, Hurtz C, Huang C, Chan LN, Swaminathan S, Sun H, Koeffler HP, Melnick A, Paietta E, Glimcher LH, Muschen M. The Plasma Cell Transcription Factor XBP1 is Required To Mitigate The Unfolded Protein Response In Ph+ ALL Blood. 122: 836-836. DOI: 10.1182/Blood.V122.21.836.836 | 0.472 | |||
| 2013 | Huang C, Haberman A, Melnick AM. The Bcl6 RD2 Domain Is Essential For Pre-Germinal Center B Cell Development Blood. 122: 783-783. DOI: 10.1182/BLOOD.V122.21.783.783 | 0.344 | |||
| 2013 | Hatzi K, Maria Nieves C, Cerchietti L, Melnick AM. The Histone Demethylase LSD1 Acts As a BCL6 Corepressor In Germinal Center B Cells Blood. 122: 781-781. DOI: 10.1182/blood.v122.21.781.781 | 0.444 | |||
| 2013 | Hurtz C, Geng H, Ballabio E, Xiao G, Ng C, Masouleh BK, Willman CL, Armstrong SA, Milne T, Melnick A, Muschen M. Identification Of BCL6 As a Therapeutic Target In MLL-Rearranged ALL Blood. 122: 72-72. DOI: 10.1182/Blood.V122.21.72.72 | 0.492 | |||
| 2013 | Shih AH, Jiang Y, Shank K, Pandey S, Viale A, Sun Y, Socci N, Robertson A, de Stanchina E, Hricik T, Rapaport F, Woods B, Cimmino L, Barreyro L, Steidl U, ... Melnick A, et al. Epigenetic Profiling Of Leukemia Stem Cells In a Model Of TET2/FLT3-Mutant AML Blood. 122: 476-476. DOI: 10.1182/Blood.V122.21.476.476 | 0.485 | |||
| 2013 | Martin P, Elstrom RL, Ruan J, Furman RR, Garcia A, Greenberg J, Rodriguez A, Bender A, Lewis J, Melnick A, Cerchietti L, Leonard JP. Phase Ib Study Of Combination Epigenetic Therapy With 5-Azacitidine and Vorinostat In Patients With Relapsed Or Refractory DLBCL Blood. 122: 4339-4339. DOI: 10.1182/Blood.V122.21.4339.4339 | 0.328 | |||
| 2013 | Culjkovic B, Fernando T, Yang S, Melnick AM, Borden KL, Cerchietti L. The Eukaryotic Translation Initiation Factor 4E (eIF4E) Has Oncogenic Functions and May Represent a New Therapeutic Target In Diffuse Large B Cell Lymphoma (DLBCL) Blood. 122: 3785-3785. DOI: 10.1182/blood.V122.21.3785.3785 | 0.377 | |||
| 2013 | Kuo P, Perumal D, Fazzari MJ, Garrett-Bakelman FE, Saba NS, Liu D, Zhang W, Brody J, Melnick AM, Dunleavy K, Wilson WH, Wiestner A, Parekh S. High-Resolution Genomic Methylation Analysis Using Next Generation Sequencing Identifies Loci Associated With Differential Prognosis In Mantle Cell Lymphoma Patients Treated With Bortezomib + DA-EPOCH-R Blood. 122: 3760-3760. DOI: 10.1182/Blood.V122.21.3760.3760 | 0.325 | |||
| 2013 | Loh ML, Harvey RC, Chen I, Devidas M, Davidsen TM, Auvil JMG, Gerhard DS, Smith MA, Carroll AJ, Heerema NA, Gastier-Foster JM, Willman CL, Mullighan CG, Hunger SP, Melnick A. Genome-Wide DNA Methylation Analysis Reveals Biological and Clinical Insights In Relapsed Childhood Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project Blood. 122: 3736-3736. DOI: 10.1182/Blood.V122.21.3736.3736 | 0.435 | |||
| 2013 | Geng H, Hurtz C, Chen Z, Chen W, Ballabio E, Xiao G, Kweon S, Nahar R, Sojaee S, Chan LN, Masouleh BK, Sykes DB, Melnick A, Roeder R, Milne T, et al. Targeting Pre-B Cell Receptor and BCL6 In TCF3-PBX1 B-Lineage Acute Lymphoblastic Leukemia Blood. 122: 349-349. DOI: 10.1182/Blood.V122.21.349.349 | 0.494 | |||
| 2013 | Li J, Julien P, An C, Hu J, Melnick A, Mohandas N, Figueroa ME. Dynamic Changes Of DNA Methylation and a Functional Role For TET2 DNA Dioxygenase In Human Erythroid Differentiation Blood. 122: 3415-3415. DOI: 10.1182/Blood.V122.21.3415.3415 | 0.398 | |||
| 2013 | Garrett-Bakelman FE, Li S, Hricik T, Chung SS, Bar H, Brown AL, Patel JP, Rapoport F, Liu L, Sheridan C, Ishii J, Zumbo P, Gandara J, Lewis ID, To LB, ... Melnick AM, et al. Epigenetic Deregulation In Relapsed Acute Myeloid Leukemia Blood. 122: 2499-2499. DOI: 10.1182/Blood.V122.21.2499.2499 | 0.34 | |||
| 2013 | Chen Z, Shojaee S, Geng H, Lee J, Buchner M, Klemm L, Lowell CA, Paietta E, Willman CL, Carroll WL, Melnick AM, Jung JU, Jumaa H, Coligan JE, Bolland S, et al. Inhibitory Receptors and Phosphatases Enable Oncogenic Tyrosine Kinase Signaling In B Cell Lineage Leukemia Blood. 122: 229-229. DOI: 10.1182/Blood.V122.21.229.229 | 0.334 | |||
| 2013 | Teater MR, Hatzi K, Popovich R, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SN, Chung YR, Shaknovich R, Creasy C, Gascoyne RD, Cerchietti L, Levine RL, Abdel-Wahab O, ... Melnick AM, et al. EZH2 and BCL6 Cooperate To Create The Germinal Center B-Cell Phenotype and Induce Lymphomas Through Formation and Repression Of Bivalent Chromatin Domains Blood. 122: 1-1. DOI: 10.1182/Blood.V122.21.1.1 | 0.637 | |||
| 2013 | Melnick A. Abstract IA20: Epigenetic deregulation of gene expression Cancer Research. 73. DOI: 10.1158/1538-7445.Cec13-Ia20 | 0.48 | |||
| 2013 | Sun X, Wang Z, Wang L, Jiang Y, Soong TD, Kost N, Chen W, Elemento O, Fischle W, Melnick A, Patel DJ, Nimer SD, Roeder RG. Abstract LB-111: A stable transcription factor complex nucleated by dimeric AML1-ETO controls leukemogenesis. Molecular and Cellular Biology. DOI: 10.1158/1538-7445.Am2013-Lb-111 | 0.437 | |||
| 2013 | Jiang Y, Redmond D, Nie K, Martin P, Melnick A, Tam W, Elemento O. Abstract 3183: Deep-sequencing reveals distinct clonal evolution patterns of DLBCL relapse and identifies mutant MLL2 as potential early driver. Cancer Research. 73: 3183-3183. DOI: 10.1158/1538-7445.Am2013-3183 | 0.358 | |||
| 2013 | Shojaee S, Buchner M, Gery S, Geng H, Chan LN, Melnick A, Koeffler PH, Müschen M. Abstract 2334: Targeting inhibitory phosphatase signaling in Ph+ ALL. Cancer Research. 73: 2334-2334. DOI: 10.1158/1538-7445.Am2013-2334 | 0.419 | |||
| 2013 | Goldstein RL, Cerchietti LC, Chiosis G, Melnick A. Abstract 2045: Oncoproteomic analysis of diffuse large B cell lymphomas reveals rationale for combination treatments. Cancer Research. 73: 2045-2045. DOI: 10.1158/1538-7445.Am2013-2045 | 0.435 | |||
| 2012 | Fontan L, Melnick A. Targeting lymphomas through MALT1 inhibition Oncotarget. 3: 1493-1494. PMID 23455603 DOI: 10.18632/Oncotarget.819 | 0.472 | |||
| 2012 | Polo JM, Anderssen E, Walsh RM, Schwarz BA, Nefzger CM, Lim SM, Borkent M, Apostolou E, Alaei S, Cloutier J, Bar-Nur O, Cheloufi S, Stadtfeld M, Figueroa ME, Robinton D, ... ... Melnick A, et al. A molecular roadmap of reprogramming somatic cells into iPS cells. Cell. 151: 1617-32. PMID 23260147 DOI: 10.1016/J.Cell.2012.11.039 | 0.376 | |||
| 2012 | Fontan L, Yang C, Kabaleeswaran V, Volpon L, Osborne MJ, Beltran E, Garcia M, Cerchietti L, Shaknovich R, Yang SN, Fang F, Gascoyne RD, Martinez-Climent JA, Glickman JF, Borden K, ... ... Melnick A, et al. MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo Cancer Cell. 22: 812-824. PMID 23238016 DOI: 10.1016/J.Ccr.2012.11.003 | 0.444 | |||
| 2012 | Alberich-Jordà M, Wouters B, Balastik M, Shapiro-Koss C, Zhang H, Di Ruscio A, DiRuscio A, Radomska HS, Ebralidze AK, Amabile G, Ye M, Zhang J, Lowers I, Avellino R, Melnick A, et al. C/EBPγ deregulation results in differentiation arrest in acute myeloid leukemia. The Journal of Clinical Investigation. 122: 4490-504. PMID 23160200 DOI: 10.1172/Jci65102 | 0.32 | |||
| 2012 | Melnick A. Epigenetic therapy leaps ahead with specific targeting of EZH2. Cancer Cell. 22: 569-70. PMID 23153531 DOI: 10.1016/J.Ccr.2012.10.016 | 0.439 | |||
| 2012 | Geng H, Brennan S, Milne TA, Chen WY, Li Y, Hurtz C, Kweon SM, Zickl L, Shojaee S, Neuberg D, Huang C, Biswas D, Xin Y, Racevskis J, Ketterling RP, ... ... Melnick AM, et al. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discovery. 2: 1004-23. PMID 23107779 DOI: 10.1158/2159-8290.Cd-12-0208 | 0.367 | |||
| 2012 | Akalin A, Kormaksson M, Li S, Garrett-Bakelman FE, Figueroa ME, Melnick A, Mason CE. methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biology. 13: R87. PMID 23034086 DOI: 10.1186/Gb-2012-13-10-R87 | 0.348 | |||
| 2012 | Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z, Mollica L, Li J, Viale A, Heguy A, Hassimi M, Socci N, Bhatt PK, Gonen M, Mason CE, ... Melnick A, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nature Genetics. 44: 1179-81. PMID 23001125 DOI: 10.1038/Ng.2413 | 0.346 | |||
| 2012 | Ouillette P, Li J, Shaknovich R, Li Y, Melnick A, Shedden K, Malek SN. Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia. Genes, Chromosomes & Cancer. 51: 1125-32. PMID 22952040 DOI: 10.1002/Gcc.21997 | 0.328 | |||
| 2012 | Kawahara M, Pandolfi A, Bartholdy B, Barreyro L, Will B, Roth M, Okoye-Okafor UC, Todorova TI, Figueroa ME, Melnick A, Mitsiades CS, Steidl U. H2.0-like homeobox regulates early hematopoiesis and promotes acute myeloid leukemia. Cancer Cell. 22: 194-208. PMID 22897850 DOI: 10.1016/J.Ccr.2012.06.027 | 0.459 | |||
| 2012 | Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH, Pandey S, Patel JP, Chung YR, Koche R, Perna F, Zhao X, Taylor JE, Park CY, Carroll M, ... Melnick A, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell. 22: 180-93. PMID 22897849 DOI: 10.1016/J.Ccr.2012.06.032 | 0.397 | |||
| 2012 | Gönen M, Sun Z, Figueroa ME, Patel JP, Abdel-Wahab O, Racevskis J, Ketterling RP, Fernandez H, Rowe JM, Tallman MS, Melnick A, Levine RL, Paietta E. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood. 120: 2297-306. PMID 22855599 DOI: 10.1182/Blood-2012-02-414425 | 0.32 | |||
| 2012 | Jiang Y, Soong TD, Wang L, Melnick AM, Elemento O. Genome-wide detection of genes targeted by Non-Ig somatic hypermutation in lymphoma Plos One. 7. PMID 22808135 DOI: 10.1371/Journal.Pone.0040332 | 0.356 | |||
| 2012 | Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brüstle A, Harris IS, Holmes R, Wakeham A, Haight J, You-Ten A, Li WY, Schalm S, Su SM, Virtanen C, ... ... Melnick A, et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature. 488: 656-9. PMID 22763442 DOI: 10.1038/Nature11323 | 0.41 | |||
| 2012 | Akalin A, Garrett-Bakelman FE, Kormaksson M, Busuttil J, Zhang L, Khrebtukova I, Milne TA, Huang Y, Biswas D, Hess JL, Allis CD, Roeder RG, Valk PJ, Löwenberg B, Delwel R, ... ... Melnick A, et al. Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. Plos Genetics. 8: e1002781. PMID 22737091 DOI: 10.1371/Journal.Pgen.1002781 | 0.404 | |||
| 2012 | Cubedo E, Gentles AJ, Huang C, Natkunam Y, Bhatt S, Lu X, Jiang X, Romero-Camarero I, Freud A, Zhao S, Bacchi CE, Martínez-Climent JA, Sánchez-García I, Melnick A, Lossos IS. Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma. Blood. 119: 5478-91. PMID 22517897 DOI: 10.1182/Blood-2012-01-403154 | 0.508 | |||
| 2012 | Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, Rockova V, Sanders M, Abbas S, Figueroa ME, Zeilemaker A, Melnick A, Löwenberg B, Valk PJ, Delwel R. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood. 119: 5824-31. PMID 22490330 DOI: 10.1182/Blood-2011-07-367961 | 0.331 | |||
| 2012 | Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci ND, Heguy A, ... ... Melnick A, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. The New England Journal of Medicine. 366: 1079-89. PMID 22417203 DOI: 10.1056/Nejmoa1112304 | 0.317 | |||
| 2012 | Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O'Rourke DM, Berger SL, Chan TA, Levine RL, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 483: 474-8. PMID 22343901 DOI: 10.1038/Nature10860 | 0.463 | |||
| 2012 | Pollyea DA, Kohrt HE, Gallegos L, Figueroa ME, Abdel-Wahab O, Zhang B, Bhattacharya S, Zehnder J, Liedtke M, Gotlib JR, Coutre S, Berube C, Melnick A, Levine R, Mitchell BS, et al. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia. 26: 893-901. PMID 22033493 DOI: 10.1038/Leu.2011.294 | 0.329 | |||
| 2012 | Kuo P, Leshchenko VV, Fazzari MJ, Gellen TA, Iqbal J, Baumgartner-Wennerholm S, Nygren L, Suh KS, Goy A, Yang DT, Chan W, Kahl BS, Verma A, Gascoyne RD, Kimby E, ... ... Melnick A, et al. SOX11 Directly Represses Wnt/β-Catenin Signaling and Identifies a Subgroup of Mantle Cell Lymphoma Patients with Improved Survival with Intensive Treatment Blood. 120: 895-895. DOI: 10.1182/Blood.V120.21.895.895 | 0.437 | |||
| 2012 | Hurtz C, Ramezani-Rad P, Geng H, Kharabi B, Carroll WL, Willman CL, Armstrong SA, Melnick A, Muschen M. Targeting BCL6-Mediated Drug-Resistance in High-Risk Childhood ALL Blood. 120: 776-776. DOI: 10.1182/Blood.V120.21.776.776 | 0.473 | |||
| 2012 | Pandolfi A, Bartholdy B, Kawahara M, Barreyro L, Will B, Stanley R, Michael R, Okoye-Okafor UC, Todorova TI, Figueroa ME, Melnick A, Mitsiades CS, Steidl U. H2.0-Like Homeobox (HLX) Induces Unlimited Clonogenicity, Blocks Differentiation, and Cooperates with FLT3-ITD in the Induction of Acute Myeloid Leukemia Blood. 120: 651-651. DOI: 10.1182/Blood.V120.21.651.651 | 0.513 | |||
| 2012 | Dupont T, Dong Z, Yang S, Melnick A, Cerchietti L. Combinatorial Targeting of BCL6 and Anti-Apoptotic Proteins in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) Blood. 120: 64-64. DOI: 10.1182/Blood.V120.21.64.64 | 0.436 | |||
| 2012 | Geng H, Nahar R, Ramezani-Rad P, Chen Z, Tyner JW, Chang BH, Titz B, Buchner M, Hurtz C, Graeber TG, Druker BJ, Paietta E, Melnick A, Willman CL, Carroll WL, et al. Integrative Analysis of Ikaros-Dependent Changes of Transcriptional Regulation and Tyrosine Phosphorylation Events in Ph+ ALL Blood. 120: 528-528. DOI: 10.1182/Blood.V120.21.528.528 | 0.462 | |||
| 2012 | Jiang Y, Hatzi K, Elemento O, Melnick A. Enhancer Profiling Reveals SOX9 As a Novel Transcription Regulator of B Cell Activation and DLBCL Transformation Blood. 120: 527-527. DOI: 10.1182/Blood.V120.21.527.527 | 0.53 | |||
| 2012 | Fong F, Bar HY, Shedden K, saiya-Cork K, Ouillette P, Campagne F, Melnick A, Malek S, Shaknovich R. Epigenetic Profiling of Primary CLL Reveals Novel DNA Methylation-Based Clusters and Novel Mechanisms of Leukemogenesis Blood. 120: 3877-3877. DOI: 10.1182/Blood.V120.21.3877.3877 | 0.457 | |||
| 2012 | Elstrom RL, Cerchietti L, Martin P, Furman RR, Yang S, Ruan J, Christos P, Coleman M, Rodriguez A, Mazumdar M, Melnick A, Leonard JP. Azacitidine Priming Prior to R-CHOP Is Feasible and Results in Global Demethylation, Restoration of TGF-Beta Pathway, and Improved Chemotherapy Sensitivity in Patients with Newly Diagnosed DLBCL Blood. 120: 3706-3706. DOI: 10.1182/Blood.V120.21.3706.3706 | 0.332 | |||
| 2012 | Schafer ES, Kostadinov R, Murakami P, Negi SS, Figueroa ME, Melnick A, Brown P. Lineage, Fusion Partner and Age Differences in the Methylome of MLL-r Leukemias Blood. 120: 3506-3506. DOI: 10.1182/Blood.V120.21.3506.3506 | 0.333 | |||
| 2012 | Bunting KL, Soong D, Jiang Y, Swed BL, Hatzi K, Shaknovich R, Reisacher W, Elemento O, Melnick A. Three-Dimensional Reorganization of the Genome During B Cell Affinity Maturation Blood. 120: 279-279. DOI: 10.1182/Blood.V120.21.279.279 | 0.495 | |||
| 2012 | Chung SS, Pang WW, In GK, Jan M, Klimek VM, Melnick A, Weissman IL, Majeti R, Park CY. CD99 Identifies Disease Stem Cells in Acute Myeloid Leukemia and the Myelodysplastic Syndromes Blood. 120: 210-210. DOI: 10.1182/Blood.V120.21.210.210 | 0.308 | |||
| 2012 | Shojaee S, Buchner M, Swaminathan S, Geng H, Chan L, Bothe M, Chen Z, Melnick A, Molkentin J, Martin G, Koeffler HP, Muschen M. Negative Feedback Signaling Enables Leukemic Transformation by Oncogenic Tyrosine Kinases Blood. 120: 1352-1352. DOI: 10.1182/Blood.V120.21.1352.1352 | 0.417 | |||
| 2012 | Swaminathan S, Kang H, Harvey RC, Huang C, Buchner M, Chen Z, Geng H, Hall A, Igarashi K, Carroll WL, Willman CL, Melnick A, Muschen M. BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor Surveillance Blood. 120: 1300-1300. DOI: 10.1182/Blood.V120.21.1300.1300 | 0.471 | |||
| 2012 | Olsson HA, Plassard A, Dexheimer P, Göttgens B, Melnick A, Aronow BJ, Grimes HL. Next Gen Dissection of Gfi1 Dependent Transcriptome in Myeloid Progenitors Reveals Global Control of Multiple Transcriptional Programs Including Coding and Non Coding RNAs Blood. 120: 111-111. DOI: 10.1182/Blood.V120.21.111.111 | 0.482 | |||
| 2012 | Rickman DS, Melnick A, Elemento O, Rubin M, Soong TD, Moss B, Mosquera JM, Dlabal J, Terry S, MacDonald T, Bunting K, Demichelis F. Abstract A31: ERG-mediated alterations in chromatin conformation Cancer Research. 72. DOI: 10.1158/1538-7445.Prca2012-A31 | 0.396 | |||
| 2012 | Walker SR, Cerchietti LC, Nicolais MC, Yuan G, Melnick A, Frank DA. Abstract 971: Identification of BCL6 targeted therapies for breast cancer through gene expression networks Cancer Research. 72: 971-971. DOI: 10.1158/1538-7445.Am2012-971 | 0.377 | |||
| 2012 | Rodina A, Moulick K, Ahn J, Zong H, Cerchietti L, DaGama EG, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, Vu L, Zhao X, Zatorska D, Taldone T, Smith-Jones P, ... ... Melnick A, et al. Abstract 3029: Biochemical evidence towards the existence of an oncogenic Hsp90 complex Cancer Research. 72: 3029-3029. DOI: 10.1158/1538-7445.Am2012-3029 | 0.425 | |||
| 2012 | Shojaee S, Buchner M, Swaminathan S, Chan L, Bothe M, Geng H, Melnick A, Molkentin J, Martin G, Koeffler P, Muschen M. Abstract 2944: Targeting negative feedback signaling in tyrosine kinase-driven malignancies Cancer Research. 72: 2944-2944. DOI: 10.1158/1538-7445.Am2012-2944 | 0.45 | |||
| 2012 | Rickman DS, Soong TD, Moss B, Mosquera JM, Dlabal J, Terry S, MacDonald T, Bunting K, Demichelis F, Melnick A, Elemento O, Rubin MA. Abstract 2222: Oncogene-mediated alterations in chromatin conformation Molecular and Cellular Biology. DOI: 10.1158/1538-7445.Am2012-2222 | 0.312 | |||
| 2012 | Melnick A. Epigenetic Therapy Leaps Ahead with Specific Targeting of EZH2 Cancer Cell. 22: 569-570. DOI: 10.1016/j.ccr.2012.10.016 | 0.329 | |||
| 2011 | Pollyea DA, Kohrt HE, Gallegos L, Zhang B, Figueroa M, Melnick A, Berube C, Coutre SE, Gotlib JR, Zehnder JL, Liedtke M, Mitchell BS, Medeiros BC. Sequential azacitidine and lenalidomide in elderly acute myeloid leukemia: completed results of the phase I study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6505. PMID 28019999 DOI: 10.1200/Jco.2011.29.15_Suppl.6505 | 0.336 | |||
| 2011 | Oricchio E, Nanjangud G, Wolfe AL, Schatz JH, Mavrakis KJ, Jiang M, Liu X, Bruno J, Heguy A, Olshen AB, Socci ND, Teruya-Feldstein J, Weis-Garcia F, Tam W, Shaknovich R, ... Melnick A, et al. The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell. 147: 554-64. PMID 22036564 DOI: 10.1016/J.Cell.2011.09.035 | 0.35 | |||
| 2011 | Cheng S, Coffey G, Zhang XH, Shaknovich R, Song Z, Lu P, Pandey A, Melnick AM, Sinha U, Wang YL. SYK inhibition and response prediction in diffuse large B-cell lymphoma Blood. 118: 6342-6352. PMID 22025527 DOI: 10.1182/blood-2011-02-333773 | 0.336 | |||
| 2011 | Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes DaGama EM, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, Vu LP, Zhao X, Zatorska D, Taldone T, Smith-Jones P, ... ... Melnick A, et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nature Chemical Biology. 7: 818-26. PMID 21946277 DOI: 10.1038/Nchembio.670 | 0.362 | |||
| 2011 | Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM, Herzog S, Ramezani-Rad P, Jumaa H, Müller MC, Hofmann WK, Hochhaus A, Ye BH, Agarwal A, Druker BJ, ... Melnick AM, et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. The Journal of Experimental Medicine. 208: 2163-74. PMID 21911423 DOI: 10.1084/Jem.20110304 | 0.311 | |||
| 2011 | Nahar R, Ramezani-Rad P, Mossner M, Duy C, Cerchietti L, Geng H, Dovat S, Jumaa H, Ye BH, Melnick A, Müschen M. Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC. Blood. 118: 4174-8. PMID 21856866 DOI: 10.1182/Blood-2011-01-331181 | 0.45 | |||
| 2011 | Shaknovich R, Cerchietti L, Tsikitas L, Kormaksson M, De S, Figueroa ME, Ballon G, Yang SN, Weinhold N, Reimers M, Clozel T, Luttrop K, Ekstrom TJ, Frank J, Vasanthakumar A, ... ... Melnick A, et al. DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. Blood. 118: 3559-69. PMID 21828137 DOI: 10.1182/Blood-2011-06-357996 | 0.428 | |||
| 2011 | Wang L, Gural A, Sun XJ, Zhao X, Perna F, Huang G, Hatlen MA, Vu L, Liu F, Xu H, Asai T, Xu H, Deblasio T, Menendez S, Voza F, ... ... Melnick A, et al. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science (New York, N.Y.). 333: 765-9. PMID 21764752 DOI: 10.1126/Science.1201662 | 0.438 | |||
| 2011 | Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, Figueroa ME, Vasanthakumar A, Patel J, Zhao X, Perna F, Pandey S, Madzo J, Song C, Dai Q, ... ... Melnick A, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 20: 11-24. PMID 21723200 DOI: 10.1016/J.Ccr.2011.06.001 | 0.357 | |||
| 2011 | Shaknovich R, Melnick A. Epigenetics and B-cell lymphoma Current Opinion in Hematology. 18: 293-299. PMID 21577103 DOI: 10.1097/Moh.0B013E32834788Cf | 0.484 | |||
| 2011 | Zhou L, Opalinska J, Sohal D, Yu Y, Mo Y, Bhagat T, Abdel-Wahab O, Fazzari M, Figueroa M, Alencar C, Zhang J, Kambhampati S, Parmar S, Nischal S, Hueck C, ... ... Melnick A, et al. Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. The Journal of Biological Chemistry. 286: 25211-23. PMID 21532034 DOI: 10.1074/Jbc.M111.235028 | 0.414 | |||
| 2011 | Cerchietti L, Damm-Welk C, Vater I, Klapper W, Harder L, Pott C, Yang SN, Reiter A, Siebert R, Melnick A, Woessmann W. Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas. Plos One. 6: e18436. PMID 21494621 DOI: 10.1371/Journal.Pone.0018436 | 0.441 | |||
| 2011 | Alvarez H, Opalinska J, Zhou L, Sohal D, Fazzari MJ, Yu Y, Montagna C, Montgomery EA, Canto M, Dunbar KB, Wang J, Roa JC, Mo Y, Bhagat T, Ramesh KH, ... ... Melnick A, et al. Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. Plos Genetics. 7: e1001356. PMID 21483804 DOI: 10.1371/Journal.Pgen.1001356 | 0.317 | |||
| 2011 | Van Vlierberghe P, Patel J, Abdel-Wahab O, Lobry C, Hedvat CV, Balbin M, Nicolas C, Payer AR, Fernandez HF, Tallman MS, Paietta E, Melnick A, Vandenberghe P, Speleman F, Aifantis I, et al. PHF6 mutations in adult acute myeloid leukemia Leukemia. 25: 130-134. PMID 21030981 DOI: 10.1038/Leu.2010.247 | 0.358 | |||
| 2011 | Lugthart S, Figueroa ME, Bindels E, Skrabanek L, Valk PJ, Li Y, Meyer S, Erpelinck-Verschueren C, Greally J, Löwenberg B, Melnick A, Delwel R. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood. 117: 234-41. PMID 20855866 DOI: 10.1182/Blood-2010-04-281337 | 0.446 | |||
| 2011 | Melnick AM, Levine RL, Figueroa ME, Thompson CB, Abdel-Wahab O. Epigenetic Effects of IDH1/IDH2 Mutations Blood. 118. DOI: 10.1182/Blood.V118.21.Sci-33.Sci-33 | 0.365 | |||
| 2011 | Winter JN, Hong F, Rimsza LM, LeBlanc M, Variakojis D, Krajewska M, Habermann TM, Melnick A, Weick JK, Pollock F, Botros I, Reed JC, Fisher RI, Kahl BS, Horning SJ, et al. Gene Risk Scores Based on Expression of 6 Genes Quanitated by Nuclease Protection Assay in Formalin Fixed Paraffin-Embedded Tissue (FFPET) Specimens From CHOP and RCHOP Treated Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Predict Outcome: An ECOG and SWOG Study Blood. 118: 87-87. DOI: 10.1182/Blood.V118.21.87.87 | 0.345 | |||
| 2011 | Kuo P, Leshchenko VV, Gellen TA, Ulahannan N, Zumbo P, Mason CE, Wilson WH, Wiestner A, Suh KS, Goy A, Yang DT, Kahl BS, Gascoyne RD, Melnick A, Parekh S. High-Resolution Chromatin Immunoprecipitation (ChIP) Sequencing Identifies Novel Binding Targets and Prognostic Role for SOX11 in Mantle Cell Lymphoma Blood. 118: 585-585. DOI: 10.1182/Blood.V118.21.585.585 | 0.469 | |||
| 2011 | Swaminathan S, Huang C, Titz B, Buchner M, Geng H, Graeber TG, Willman CL, Igarashi K, Melnick A, Muschen M. BACH2 Mediates Early B Cell Differentiation and Oncogene-Induced Senescence in Acute Lymphoblastic Leukemia Blood. 118: 562-562. DOI: 10.1182/Blood.V118.21.562.562 | 0.485 | |||
| 2011 | Bunting KL, Soong TD, Chatzi K, Jiang Y, Elemento O, Melnick A. A Role for BCL6 in the Higher-Order Organization of Genes in DLBCL Blood. 118: 558-558. DOI: 10.1182/Blood.V118.21.558.558 | 0.511 | |||
| 2011 | Chambwe N, Kormaksson M, De S, Michor F, Johnson N, Scott DW, Gascoyne RD, Melnick A, Campagne F, Shaknovich R. Epigenetic Profiling of Primary DLBCLs Reveals Novel DNA Methylation-Based Clusters and New Underlying Mechanisms of Lymphomagenesis Blood. 118: 556-556. DOI: 10.1182/Blood.V118.21.556.556 | 0.423 | |||
| 2011 | Hurtz C, Hatzi K, Cerchietti L, Park E, Kim Y, Ramezani-Rad P, Jumaa H, Muller MC, Hofmann W, Hochhaus A, Agarwal A, Shah N, Melnick A, Druker BJ, Muschen M. BCL6-Mediated Repression of p53 Is Critical for Leukemia Stem Cell Survival in Chronic Myeloid Leukemia Blood. 118: 446-446. DOI: 10.1182/Blood.V118.21.446.446 | 0.467 | |||
| 2011 | Cubedo E, Gentles AJ, Huang C, Natkunam Y, Bhatt S, Jiang X, Lu X, Romero-Camarero I, Plevritis SK, Martinez-Climent JA, Sanchez-Garcia I, Melnick A, Lossos IS. Identification of LMO2 Transcriptome and Interactome in Diffuse Large B-Cell Lymphoma by Integrated Experimental and Computational Approach Blood. 118: 438-438. DOI: 10.1182/Blood.V118.21.438.438 | 0.502 | |||
| 2011 | Abdel-Wahab O, Adli M, Saunders L, Gao J, Shih AH, Pandey S, Jaffe J, Zhao X, Perna F, Carroll M, Melnick A, Nimer SD, Aifantis I, Bernstein B, Levine RL. ASXL1 Mutations Promote Myeloid Transformation Through Inhibition of PRC2-Mediated Gene Repression Blood. 118: 405-405. DOI: 10.1182/Blood.V118.21.405.405 | 0.482 | |||
| 2011 | Ruan J, Cerchietti L, Wang C, Fan L, Yang SN, Geng H, Leonard JP, Melnick A, Hajjar KA. Therapeutic Targeting of Lymphoma-Associated Vascular Pericytes, Blood. 118: 3725-3725. DOI: 10.1182/Blood.V118.21.3725.3725 | 0.405 | |||
| 2011 | Jiang Y, Soong D, Huang C, Monni S, Melnick A, Elemento O. Genomewide Detection of Genes Targeted by Aberrant Somatic Hypermutation in Lymphoma Blood. 118: 3474-3474. DOI: 10.1182/Blood.V118.21.3474.3474 | 0.539 | |||
| 2011 | Figueroa ME, Malinge S, Chlon TM, Li Y, Paietta E, Fernandez HF, Tallman MS, Weiss MJ, Chou ST, Melnick A, Crispino J. Development of Acute Megakaryoblastic Leukemia in Down Syndrome Is Associated with Sequential Epigenetic Changes That Target the Down Syndrome Critical Region on Chromosome 21, Blood. 118: 3451-3451. DOI: 10.1182/Blood.V118.21.3451.3451 | 0.415 | |||
| 2011 | Clozel T, Yang S, Kormaksson M, Elstrom R, Vasanthakumar A, Brennan S, Culjkovic B, Leser M, Martin P, Borden KL, Wang YL, Cheng S, Tam W, Shaknovich R, Chadburn A, ... Melnick A, et al. Chemosensitization of Diffuse Large B Cell Lymphoma by Demethylating Nucleoside Analogues Blood. 118: 1617-1617. DOI: 10.1182/Blood.V118.21.1617.1617 | 0.479 | |||
| 2011 | Shojaee S, Buchner M, Geng H, Melnick A, Gery S, Molkentin J, Koeffler P, Muschen M. DUSP6-Mediated Negative Feedback to Oncogenic Tyrosine Kinase Signaling Prevents Excessive Accumulation of ROS and Enables Leukemia Cell Survival Blood. 118: 1479-1479. DOI: 10.1182/Blood.V118.21.1479.1479 | 0.464 | |||
| 2011 | Bertolo C, Malumbres R, Sagardoy A, Robles EF, Martinez-Ferrandis JI, Roa S, Lossos IS, Sagaert X, Melnick A, Amar S, Martinez-Climent JA. LITAF, a BCL6 Target Gene, Regulates Autophagia in B Cells and Is Essential for T-Cell Dependent Humoral Responses Blood. 118: 1391-1391. DOI: 10.1182/Blood.V118.21.1391.1391 | 0.472 | |||
| 2011 | Olsson HA, Plassard A, Dexheimer P, Phelan JD, Melnick A, Xia J, Link DC, Opferman J, Aronow BJ, Grimes HL. Conserved Transcriptional Deregulation Underlies GFI1 and ELANE Mutant Neutropenia Blood. 118: 13-13. DOI: 10.1182/Blood.V118.21.13.13 | 0.473 | |||
| 2011 | Rickman DS, Soong TD, Moss B, Kitabayashi N, Bunting K, Naseeruddin S, Garraway LA, Berger MF, Melnick A, Elemento O, Rubin MA. Abstract LB-249: Oncogene-mediated alterations in chromatin conformation Cancer Research. 71: 2222-2222. DOI: 10.1158/1538-7445.Am2011-Lb-249 | 0.394 | |||
| 2011 | Duy C, Hurtz C, Koeffler PH, Melnick AM, Müschen M. Abstract LB-235: BCL6 enables Ph+ acute lymphoblastic leukemia cells to survive BCR-ABL1 kinase inhibition Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-235 | 0.328 | |||
| 2011 | Rodina A, Kang Y, Taldone T, Patel H, Patel P, Caldas-Lopes E, Erdjument-Bromage H, Guzman M, Young JC, Melnick A, Chiosis G. Abstract 2579: YK5, a small molecule inhibitor of Hsp70 and Hsc70, reveals a multifaceted role for the Hsp70 chaperones in regulating oncogenic and non-oncogenic addiction of tumors Cancer Research. 71: 2579-2579. DOI: 10.1158/1538-7445.Am2011-2579 | 0.349 | |||
| 2010 | Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, ... Melnick A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 18: 553-67. PMID 21130701 DOI: 10.1016/J.Ccr.2010.11.015 | 0.58 | |||
| 2010 | Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA, Bhalla K, Gascoyne RD, Marra M, Chiosis G, Melnick A. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. The Journal of Clinical Investigation. 120: 4569-82. PMID 21041953 DOI: 10.1172/Jci42869 | 0.488 | |||
| 2010 | Velichutina I, Shaknovich R, Geng H, Johnson NA, Gascoyne RD, Melnick AM, Elemento O. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood. 116: 5247-55. PMID 20736451 DOI: 10.1182/blood-2010-04-280149 | 0.426 | |||
| 2010 | Polo JM, Liu S, Figueroa ME, Kulalert W, Eminli S, Tan KY, Apostolou E, Stadtfeld M, Li Y, Shioda T, Natesan S, Wagers AJ, Melnick A, Evans T, Hochedlinger K. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nature Biotechnology. 28: 848-55. PMID 20644536 DOI: 10.1038/Nbt.1667 | 0.414 | |||
| 2010 | Murphy MW, Sarver AL, Rice D, Hatzi K, Ye K, Melnick A, Heckert LL, Zarkower D, Bardwell VJ. Genome-wide analysis of DNA binding and transcriptional regulation by the mammalian Doublesex homolog DMRT1 in the juvenile testis. Proceedings of the National Academy of Sciences of the United States of America. 107: 13360-5. PMID 20616082 DOI: 10.1073/Pnas.1006243107 | 0.48 | |||
| 2010 | Shaknovich R, Geng H, Johnson NA, Tsikitas L, Cerchietti L, Greally JM, Gascoyne RD, Elemento O, Melnick A. DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood. 116: e81-9. PMID 20610814 DOI: 10.1182/Blood-2010-05-285320 | 0.486 | |||
| 2010 | Shah MY, Vasanthakumar A, Barnes NY, Figueroa ME, Kamp A, Hendrick C, Ostler KR, Davis EM, Lin S, Anastasi J, Le Beau MM, Moskowitz IP, Melnick A, Pytel P, Godley LA. DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis. Cancer Research. 70: 5840-50. PMID 20587527 DOI: 10.1158/0008-5472.CAN-10-0847 | 0.306 | |||
| 2010 | Elstrom RL, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, Ruan J, Shore T, Schuster M, Cerchietti L, Melnick A, Coleman M, Leonard JP. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clinical Lymphoma, Myeloma & Leukemia. 10: 192-6. PMID 20511164 DOI: 10.3816/Clml.2010.N.030 | 0.356 | |||
| 2010 | Duy C, Yu JJ, Nahar R, Swaminathan S, Kweon SM, Polo JM, Valls E, Klemm L, Shojaee S, Cerchietti L, Schuh W, Jäck HM, Hurtz C, Ramezani-Rad P, Herzog S, ... Melnick AM, et al. BCL6 is critical for the development of a diverse primary B cell repertoire. The Journal of Experimental Medicine. 207: 1209-21. PMID 20498019 DOI: 10.1084/Jem.20091299 | 0.333 | |||
| 2010 | Leshchenko VV, Kuo PY, Shaknovich R, Yang DT, Gellen T, Petrich A, Yu Y, Remache Y, Weniger MA, Rafiq S, Suh KS, Goy A, Wilson W, Verma A, Braunschweig I, ... ... Melnick A, et al. Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood. 116: 1025-34. PMID 20427703 DOI: 10.1182/Blood-2009-12-257485 | 0.471 | |||
| 2010 | Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M, Bunting KL, Polo JM, Farès C, Arrowsmith CH, Yang SN, Garcia M, Coop A, Mackerell AD, Privé GG, ... Melnick A, et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell. 17: 400-11. PMID 20385364 DOI: 10.1016/J.Ccr.2009.12.050 | 0.397 | |||
| 2010 | Winter JN, Li S, Aurora V, Variakojis D, Nelson B, Krajewska M, Zhang L, Habermann TM, Fisher RI, Macon WR, Chhanabhai M, Felgar RE, Hsi ED, Medeiros LJ, Weick JK, ... ... Melnick A, et al. Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2435-42. PMID 20371683 DOI: 10.1158/1078-0432.Ccr-09-1219 | 0.338 | |||
| 2010 | Cairo MS, Jordan CT, Maley CC, Chao C, Melnick A, Armstrong SA, Shlomchik W, Molldrem J, Ferrone S, Mackall C, Zitvogel L, Bishop MR, Giralt SA, June CH. NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 16: 709-28. PMID 20227509 DOI: 10.1016/J.Bbmt.2010.03.002 | 0.344 | |||
| 2010 | Shaknovich R, Figueroa ME, Melnick A. HELP (HpaII tiny fragment enrichment by ligation-mediated PCR) assay for DNA methylation profiling of primary normal and malignant B lymphocytes. Methods in Molecular Biology (Clifton, N.J.). 632: 191-201. PMID 20217579 DOI: 10.1007/978-1-60761-663-4_12 | 0.422 | |||
| 2010 | Schafer E, Irizarry R, Negi S, McIntyre E, Small D, Figueroa ME, Melnick A, Brown P. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. Blood. 115: 4798-809. PMID 20215641 DOI: 10.1182/Blood-2009-09-243634 | 0.37 | |||
| 2010 | Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J, van Putten W, Skrabanek L, Campagne F, Mazumdar M, Greally JM, Valk PJ, Löwenberg B, ... ... Melnick A, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 17: 13-27. PMID 20060365 DOI: 10.1016/J.Ccr.2009.11.020 | 0.397 | |||
| 2010 | Hammerich-Hille S, Kaipparettu BA, Tsimelzon A, Creighton CJ, Jiang S, Polo JM, Melnick A, Meyer R, Oesterreich S. SAFB1 mediates repression of immune regulators and apoptotic genes in breast cancer cells. The Journal of Biological Chemistry. 285: 3608-16. PMID 19901029 DOI: 10.1074/Jbc.M109.066431 | 0.416 | |||
| 2010 | Geng H, Neuberg D, Paietta E, Deng X, Li Y, Xin Y, Racevskis J, Ketterling R, Richards SM, Tallman MS, Rowe JM, Litzow MR, Elemento O, Melnick AM. Integrative Genome-Wide DNA Methylation and Gene Expression Analysis Reveals Biological and Clinical Insights In Adult Acute Lymphoblastic Leukemia Blood. 116: 852-852. DOI: 10.1182/blood.v116.21.852.852 | 0.32 | |||
| 2010 | Matthews JM, Natkunam Y, Srinivasan S, Patricelli M, Nomanbhoy T, Cerchietti L, Melnick AM, Lossos IS. STAT3, Constitutively Activated In ABC-Like DLBCL, Regulates Expression of the Prognostic Factor Cyclin D2 Blood. 116: 705-705. DOI: 10.1182/Blood.V116.21.705.705 | 0.372 | |||
| 2010 | Figueroa ME, Chen S, Andersson AK, Liu W, Cheng C, Phillips LA, Li Y, Downing JR, Melnick AM, Mullighan C. Integrated Genetic and Epigenetic Analysis of Childhood Acute Lymphoblastic Leukemia Reveals a Synergistic Role for Structural and Epigenetic Lesions In Determining Disease Phenotype Blood. 116: 537-537. DOI: 10.1182/Blood.V116.21.537.537 | 0.363 | |||
| 2010 | Hurtz C, Duy C, Cerchietti L, Chatzi K, Park E, Klemm L, Kim Y, Kahn M, Braig M, Muller MC, Hochhaus A, Ye BH, Melnick AM, Muschen M. BCL6 Is Required for the Maintenance of Leukemia-Initiating Cells In Chronic Myeloid Leukemia Blood. 116: 202-202. DOI: 10.1182/Blood.V116.21.202.202 | 0.394 | |||
| 2010 | Nahar R, Ramezani-Rad P, Duy C, Dovat S, Ye BH, Melnick AM, Muschen M. IKAROS and BCL6 Limit Pre-B Cell Expansion and Prevent Leukemogenesis Downstream of the Pre-B Cell Receptor Blood. 116: 146-146. DOI: 10.1182/Blood.V116.21.146.146 | 0.344 | |||
| 2010 | Lopes EC, Bos P, Peinado H, Cerchietti L, Lavotshkin S, Melnick A, Lyden D, Chiosis G. Abstract 5766: The Hsp90 inhibitor PU-H71 is a potent suppressor of metastasis in triple-negative breast cancer models Cancer Research. 70: 5766-5766. DOI: 10.1158/1538-7445.Am10-5766 | 0.328 | |||
| 2010 | Rodina A, Kang Y, Maharaj R, Gozman A, Taldone T, Cerchietti L, Wong MJH, Baaklini I, Caldas-Lopes E, Clement CC, Brodsky J, Erdjument-Bromage H, Ma Y, Melnick A, Young JC, et al. Abstract 5463: YK5, a novel dual Hsc70 and Hsp70 inhibitor, is selective for tumor Hsp70 and has potent but selective activity in cancer cells Cancer Research. 70: 5463-5463. DOI: 10.1158/1538-7445.Am10-5463 | 0.36 | |||
| 2010 | Taylor KH, Shaknovich R, Martin-Subero J, Arthur G, Bennett L, Ammerpohl O, Richter J, Siebert R, Melnick A, Caldwell C. Abstract 168: Genome-wide survey of CpG methylation across the spectrum of B-cell lymphomas Cancer Research. 70: 168-168. DOI: 10.1158/1538-7445.Am10-168 | 0.477 | |||
| 2009 | Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L, Shaknovich R, Bhalla KN, Chiosis G, Melnick A. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nature Medicine. 15: 1369-76. PMID 19966776 DOI: 10.1038/Nm.2059 | 0.433 | |||
| 2009 | Juszczynski P, Chen L, O'Donnell E, Polo JM, Ranuncolo SM, Dalla-Favera R, Melnick A, Shipp MA. BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt. Blood. 114: 5315-21. PMID 19855081 DOI: 10.1182/Blood-2009-02-204362 | 0.486 | |||
| 2009 | Figueroa ME, Skrabanek L, Li Y, Jiemjit A, Fandy TE, Paietta E, Fernandez H, Tallman MS, Greally JM, Carraway H, Licht JD, Gore SD, Melnick A. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood. 114: 3448-58. PMID 19652201 DOI: 10.1182/Blood-2009-01-200519 | 0.598 | |||
| 2009 | Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y, Wu N, de Stanchina E, White J, Gross SS, Ma Y, ... ... Melnick A, et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proceedings of the National Academy of Sciences of the United States of America. 106: 8368-73. PMID 19416831 DOI: 10.1073/Pnas.0903392106 | 0.352 | |||
| 2009 | Oda M, Glass JL, Thompson RF, Mo Y, Olivier EN, Figueroa ME, Selzer RR, Richmond TA, Zhang X, Dannenberg L, Green RD, Melnick A, Hatchwell E, Bouhassira EE, Verma A, et al. High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers. Nucleic Acids Research. 37: 3829-39. PMID 19386619 DOI: 10.1093/Nar/Gkp260 | 0.31 | |||
| 2009 | Ci W, Polo JM, Cerchietti L, Shaknovich R, Wang L, Yang SN, Ye K, Farinha P, Horsman DE, Gascoyne RD, Elemento O, Melnick A. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood. 113: 5536-48. PMID 19307668 DOI: 10.1182/Blood-2008-12-193037 | 0.515 | |||
| 2009 | Figueroa ME, Melnick A, Greally JM. Genome-wide determination of DNA methylation by Hpa II tiny fragment enrichment by ligation-mediated PCR (HELP) for the study of acute leukemias. Methods in Molecular Biology (Clifton, N.J.). 538: 395-407. PMID 19277580 DOI: 10.1007/978-1-59745-418-6_20 | 0.38 | |||
| 2009 | Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, Elstrom R, Niesvizky R, Ely S, Diliberto M, Melnick A, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP. Outcome of deferred initial therapy in mantle-cell lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1209-13. PMID 19188674 DOI: 10.1200/Jco.2008.19.6121 | 0.334 | |||
| 2009 | Figueroa ME, Wouters BJ, Skrabanek L, Glass J, Li Y, Erpelinck-Verschueren CA, Langerak AW, Löwenberg B, Fazzari M, Greally JM, Valk PJ, Melnick A, Delwel R. Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. Blood. 113: 2795-804. PMID 19168792 DOI: 10.1182/Blood-2008-08-172387 | 0.462 | |||
| 2009 | Laurenzana A, Petruccelli LA, Pettersson F, Figueroa ME, Melnick A, Baldwin AS, Paoletti F, Miller WH. Inhibition of DNA methyltransferase activates tumor necrosis factor alpha-induced monocytic differentiation in acute myeloid leukemia cells. Cancer Research. 69: 55-64. PMID 19117987 DOI: 10.1158/0008-5472.Can-08-0245 | 0.459 | |||
| 2009 | Cerchietti LC, Yang SN, Shaknovich R, Hatzi K, Polo JM, Chadburn A, Dowdy SF, Melnick A. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood. 113: 3397-405. PMID 18927431 DOI: 10.1182/Blood-2008-07-168773 | 0.388 | |||
| 2009 | Duy C, Yu JJ, Swaminathan S, Nahar RR, Kweon S, Polo JM, Valls E, Klemm L, Cerchietti L, Levetzow Gv, Herzog S, Jumaa H, Alborán IMd, Melnick A, Ye BH, et al. BCL6 Is Critical for the Development of a Diverse Primary B Cell Repertoire. Blood. 114: 91-91. DOI: 10.1182/Blood.V114.22.91.91 | 0.446 | |||
| 2009 | Duy C, Cerchietti L, Yu JJ, Ci W, Swaminathan S, Nahar RR, Kweon S, Klemm L, Ye BH, Melnick A, Müschen M. BCL6-Dependent Negative Regulation of Cell Cycle Checkpoint Regulators Enables Drug-Resistance in Ph+ Acute Lymphoblastic Leukemia. Blood. 114: 765-765. DOI: 10.1182/Blood.V114.22.765.765 | 0.445 | |||
| 2009 | Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J, Skrabanek L, Campagne F, Mazumdar M, Greally J, Valk P, Lowenberg B, Delwel R, ... Melnick A, et al. DNA Methylation Profiling Predicts Clinical Outcomes and Reveals Unique Insights Into the Molecular Complexity of Acute Myeloid Leukemia. Blood. 114: 707-707. DOI: 10.1182/Blood.V114.22.707.707 | 0.371 | |||
| 2009 | Leshchenko V, Kuo P, Shaknovich R, Gellen T, Remache Y, Weniger M, Suh KS, Goy A, Wilson W, Braunschweig I, Verma A, Wiestner A, Melnick A, Parekh S. Genome-Wide Methylation Analysis of Primary Mantle Cell Lymphomas Identifies Novel Gene Targets for Epigenetic Drug Therapy. Blood. 114: 673-673. DOI: 10.1182/Blood.V114.22.673.673 | 0.498 | |||
| 2009 | Shaknovich R, Geng H, Johnson N, Cerchietti L, Figueroa ME, Tsikitas L, Elemento O, Connors JM, Sehn L, Gascoyne RD, Melnick A. ABC and GCB DLBCLs Display Unique Biologically Distinct and Clinically Relevant Epigenetic Signatures. Blood. 114: 619-619. DOI: 10.1182/Blood.V114.22.619.619 | 0.456 | |||
| 2009 | Schafer ES, Irizarry R, Negi S, McIntyre E, Small D, Figueroa ME, Melnick A, Brown P. Promoter Hypermethylation in MLL-r Leukemia: Biology and Therapeutic Targeting. Blood. 114: 3472-3472. DOI: 10.1182/Blood.V114.22.3472.3472 | 0.418 | |||
| 2009 | Velichutina I, Shaknovich R, Geng H, Melnick A, Elemento O. EZH2 Mediates DNA Methylation-Independent Epigenetic Silencing of a Germinal Center Specific Transcriptional Program That Contributes to Cellular Proliferation and Lymphomagenesis. Blood. 114: 3465-3465. DOI: 10.1182/Blood.V114.22.3465.3465 | 0.51 | |||
| 2009 | Hurtz C, Duy C, Cerchietti L, Park E, Ci W, Swaminathan S, Kweon S, Klemm L, Kim Y, Martinelli G, Hofmann W, Ye BH, Melnick A, Müschen M. BCL6 Is Required for Leukemia-Initiation and Self-Renewal Signaling in Chronic Myeloid Leukemia. Blood. 114: 2167-2167. DOI: 10.1182/Blood.V114.22.2167.2167 | 0.47 | |||
| 2009 | Cerchietti LC, Ghetu A, Zhu X, Silva GD, Zhong S, Matthews M, Polo J, Farès C, Arrowsmith C, Bunting K, Coop A, MacKerell A, Privè G, Melnick A. Abstract B236: A small molecule disrupts the BCL6 transcriptional repressor complex and kills lymphoma cells in vitro and in vivo Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B236 | 0.46 | |||
| 2008 | Lopes EC, Valls E, Figueroa ME, Mazur A, Meng FG, Chiosis G, Laird PW, Schreiber-Agus N, Greally JM, Prokhortchouk E, Melnick A. Kaiso contributes to DNA methylation-dependent silencing of tumor suppressor genes in colon cancer cell lines. Cancer Research. 68: 7258-63. PMID 18794111 DOI: 10.1158/0008-5472.Can-08-0344 | 0.447 | |||
| 2008 | Sohal D, Yeatts A, Ye K, Pellagatti A, Zhou L, Pahanish P, Mo Y, Bhagat T, Mariadason J, Boultwood J, Melnick A, Greally J, Verma A. Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration. Plos One. 3: e2965. PMID 18698424 DOI: 10.1371/Journal.Pone.0002965 | 0.405 | |||
| 2008 | Wilson AJ, Byun DS, Nasser S, Murray LB, Ayyanar K, Arango D, Figueroa M, Melnick A, Kao GD, Augenlicht LH, Mariadason JM. HDAC4 promotes growth of colon cancer cells via repression of p21. Molecular Biology of the Cell. 19: 4062-75. PMID 18632985 DOI: 10.1091/Mbc.E08-02-0139 | 0.43 | |||
| 2008 | Ci W, Polo JM, Melnick A. B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma. Current Opinion in Hematology. 15: 381-390. PMID 18536578 DOI: 10.1097/Moh.0B013E328302C7Df | 0.496 | |||
| 2008 | Ranuncolo SM, Wang L, Polo JM, Dell'Oso T, Dierov J, Gaymes TJ, Rassool F, Carroll M, Melnick A. BCL6-mediated attenuation of DNA damage sensing triggers growth arrest and senescence through a p53-dependent pathway in a cell context-dependent manner Journal of Biological Chemistry. 283: 22565-22572. PMID 18524763 DOI: 10.1074/Jbc.M803490200 | 0.481 | |||
| 2008 | Polo JM, Ci W, Licht JD, Melnick A. Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells Blood. 112: 644-651. PMID 18487509 DOI: 10.1182/Blood-2008-01-131813 | 0.616 | |||
| 2008 | Parekh S, Prive G, Melnick A. Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas Leukemia and Lymphoma. 49: 874-882. PMID 18452090 DOI: 10.1080/10428190801895345 | 0.5 | |||
| 2008 | Cerchietti LC, Polo JM, Da Silva GF, Farinha P, Shaknovich R, Gascoyne RD, Dowdy SF, Melnick A. Sequential transcription factor targeting for diffuse large B-cell lymphomas. Cancer Research. 68: 3361-9. PMID 18451163 DOI: 10.1158/0008-5472.Can-07-5817 | 0.456 | |||
| 2008 | Figueroa ME, Reimers M, Thompson RF, Ye K, Li Y, Selzer RR, Fridriksson J, Paietta E, Wiernik P, Green RD, Greally JM, Melnick A. An integrative genomic and epigenomic approach for the study of transcriptional regulation. Plos One. 3: e1882. PMID 18365023 DOI: 10.1371/Journal.Pone.0001882 | 0.461 | |||
| 2008 | Ranuncolo SM, Polo JM, Melnick A. BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells. Blood Cells Molecules and Diseases. 41: 95-99. PMID 18346918 DOI: 10.1016/J.Bcmd.2008.02.003 | 0.491 | |||
| 2008 | Ghetu AF, Corcoran CM, Cerchietti L, Bardwell VJ, Melnick A, Privé GG. Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer. Molecular Cell. 29: 384-91. PMID 18280243 DOI: 10.1016/J.Molcel.2007.12.026 | 0.303 | |||
| 2008 | Mendez LM, Polo JM, Yu JJ, Krupski M, Ding BB, Melnick A, Ye BH. CtBP is an essential corepressor for BCL6 autoregulation. Molecular and Cellular Biology. 28: 2175-86. PMID 18212045 DOI: 10.1128/Mcb.01400-07 | 0.502 | |||
| 2008 | Leshchenko V, Melnick A, Parekh SS. Activity and epigenetic determinants of sensitivity to temozolomide in diffuse large B cell lymphoma Journal of Clinical Oncology. 26: 19523-19523. DOI: 10.1200/Jco.2008.26.15_Suppl.19523 | 0.436 | |||
| 2008 | Figueroa ME, Greally J, Delwel R, Melnick AM. Genome-Wide Epigenetics in Myeloid Leukemias. Blood. 112: sci-35-sci-35. DOI: 10.1182/Blood.V112.11.Sci-35.Sci-35 | 0.341 | |||
| 2008 | Lugthart S, Figueroa ME, Valk PJ, Li Y, Erpelinck-Verschueren C, Greally J, Löwenberg B, Melnick A, Delwel R. Two Different EVI1 Expressing Poor-Risk AML Subgroups with Distinct Epigenetic Signatures Uncovered by Genome Wide DNA Methylation Profiling Blood. 112: 757-757. DOI: 10.1182/Blood.V112.11.757.757 | 0.468 | |||
| 2008 | Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Christos PJ, Mazumdar M, Löwenberg B, Greally J, Valk PJ, Delwel R, Melnick A. Epigenetic Signatures Identify New Clinically Relevant Subtypes and Define Gene Regulatory Patterns in Patients with Acute Myeloid Leukemia (AML) Blood. 112: 756-756. DOI: 10.1182/Blood.V112.11.756.756 | 0.329 | |||
| 2008 | Lopes EC, Cerchietti L, Yang SN, Melnick A, Chiosis G. Antitumor Efficacy of the Purine-Scaffold Hsp90 Inhibitor PU-H71 in Diffuse Large-B Cell Lymphoma Blood. 112: 602-602. DOI: 10.1182/Blood.V112.11.602.602 | 0.358 | |||
| 2008 | Gellen T, Kuo P, Shaknovich R, Figueroa ME, Melnick A, Wiestner A, Parekh S. Epigenetic Determinants of Pathogenesis and Resistance to Proteosome Inhibition in Mantle Cell Lymphoma. Blood. 112: 3373-3373. DOI: 10.1182/Blood.V112.11.3373.3373 | 0.489 | |||
| 2008 | Duy C, Yu JJ, Cerchietti L, Klemm L, Nahar R, Kim Y, Heisterkamp N, Martinelli G, Hofmann W, Jumaa H, Melnick A, Ye BH, Muschen M. BCL6-Mediated Survival Signaling Promotes Drug-Resistance in BCRABL1- Driven Acute Lymphoblastic Leukemia Blood. 112: 295-295. DOI: 10.1182/Blood.V112.11.295.295 | 0.415 | |||
| 2007 | Melnick A. Targeting aggressive B-cell lymphomas with cell-penetrating peptides Biochemical Society Transactions. 35: 802-806. PMID 17635152 DOI: 10.1042/Bst0350802 | 0.412 | |||
| 2007 | Ranuncolo SM, Polo JM, Dierov J, Singer M, Kuo T, Greally J, Green R, Carroll M, Melnick A. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nature Immunology. 8: 705-14. PMID 17558410 DOI: 10.1038/Ni1478 | 0.48 | |||
| 2007 | Parekh S, Polo JM, Shaknovich R, Juszczynski P, Lev P, Ranuncolo SM, Yin Y, Klein U, Cattoretti G, Dalla Favera R, Shipp MA, Melnick A. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood. 110: 2067-74. PMID 17545502 DOI: 10.1182/Blood-2007-01-069575 | 0.496 | |||
| 2007 | Polo JM, Juszczynski P, Monti S, Cerchietti L, Ye K, Greally JM, Shipp M, Melnick A. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America. 104: 3207-12. PMID 17360630 DOI: 10.1073/Pnas.0611399104 | 0.499 | |||
| 2007 | Melnick A. Targeting APL fusion proteins by peptide interference. Current Topics in Microbiology and Immunology. 313: 221-243. PMID 17217046 DOI: 10.1007/978-3-540-34594-7_12 | 0.343 | |||
| 2007 | Da Silva GF, Ghetu A, Cerchietti L, Polo JM, Coop A, Mackerell A, Prive GG, Melnick A. Design and Development of Small Molecules for Specific Targeted Therapy of Diffuse Large B-Cell Lymphoma. Blood. 110: 799-799. DOI: 10.1182/Blood.V110.11.799.799 | 0.459 | |||
| 2007 | Shaknovich R, Cerchietti L, Figueroa ME, Melnick A. DNA Methyltransferase 1 Contributes to Epigenetic Signatures and Biological Phenotype during Normal B-Cell Differentiation and Lymphomagenesis. Blood. 110: 685-685. DOI: 10.1182/Blood.V110.11.685.685 | 0.502 | |||
| 2007 | Ci W, Polo JM, Ranuncolo SM, Melnick A. A “Survival of the Fittest” Mechanism for Weeding Out Potentially Lymphomagenic B-Cells during Germinal Center B-Cell Differentiation. Blood. 110: 559-559. DOI: 10.1182/Blood.V110.11.559.559 | 0.497 | |||
| 2007 | Cerchietti L, Figueroa ME, Meyers D, Cole PA, Bhalla K, Melnick A. Connectivity Mapping of BCL6 Targeted Therapy Guides Rational Design of Potent and Specific Non-Chemotherapy Combinatorial Regimens in DLBCL. Blood. 110: 523-523. DOI: 10.1182/Blood.V110.11.523.523 | 0.452 | |||
| 2007 | Sohal D, Yeatts A, Ye K, Pellagatti A, Zhou L, Pahanish P, Mariadason J, Melnick A, Greally J, Boultwood J, Verma A. Data Mining of Hematopoietic Stem Cell Microarray Studies Reveals a Novel Stem Cell Gene Expression Signature and Demonstrates Feasibility of Integrating Data from Different Labs and Different Microarray Platforms. Blood. 110: 4073-4073. DOI: 10.1182/Blood.V110.11.4073.4073 | 0.412 | |||
| 2007 | Mendez LM, Polo J, Krupski M, Yu J, Melnick AM, Ye B. CtBP1 Is a Novel and Essential Corepressor for BCL6 Autoregulation. Blood. 110: 3581-3581. DOI: 10.1182/BLOOD.V110.11.3581.3581 | 0.439 | |||
| 2007 | Figueroa ME, Fandy T, McConnell MJ, Berkofsky-Fessler W, Nasrallah C, Carraway H, Licht J, Gore SD, Melnick AM. Myelodysplastic Syndrome (MDS) Displays Profound and Functionally Significant Epigenetic Deregulation Compared to Acute Myeloid Leukemia (AML) and Normal Bone Marrow Cells. Blood. 110: 345-345. DOI: 10.1182/Blood.V110.11.345.345 | 0.579 | |||
| 2007 | Perez-Caro M, Cobaleda C, Piris MA, Melnick AM, Snachez-Garcia I. The BCL6 Oncogene Drives an Epigenomic Program Linking Stem Cells to the Pathogenesis of Human Diffuse Large B Cell Lymphoma in Mice. Blood. 110: 3372-3372. DOI: 10.1182/BLOOD.V110.11.3372.3372 | 0.385 | |||
| 2007 | Polo JM, Chatzi K, Dell’Oso T, Lev P, Melnick A. BCL6 Transcriptionally Reprograms the DLBCL Genome by Forming Distinct Biochemically Active Complexes on Genes Corresponding to Different Pathways. Blood. 110: 2646-2646. DOI: 10.1182/Blood.V110.11.2646.2646 | 0.474 | |||
| 2007 | Zhou L, Opalinska J, Sohal D, Thompson R, Li Y, Kotla V, Pahanish P, Parmar S, Kambhampati S, Figueroa M, Ye K, Friedman E, Wickrema A, Melnick A, Greally J, et al. Global Epigenomic Profiling Demonstrates That Myelodysplasia Is Characterized by a Distinct Epigenetic Signature with Aberrant DNA Methylation Changes Involving Various Malignant and Hematopoietic Pathways. Blood. 110: 2436-2436. DOI: 10.1182/Blood.V110.11.2436.2436 | 0.432 | |||
| 2007 | Opalinska J, Daibata M, Sohal D, Zhou L, Thompson R, Pahanish P, Affer M, Figueroa M, Ye K, Greally J, Bai F, List A, Melnick A, Epling-Burnette P, Verma A. Integrated Epigenomic Profiling Reveals Aberrant DNA Hypomethylation in LGL and Demonstrates That a Combination of Genetic and Epigenetic Events Results in Leukemic Evolution in Model of Large Granular Lymphocytic Leukemia. Blood. 110: 2129-2129. DOI: 10.1182/Blood.V110.11.2129.2129 | 0.468 | |||
| 2007 | Sohal D, Opalinska J, Zhou L, Pahanish P, Friedman E, Thompson R, Ye K, Figueroa M, Melnick A, Greally J, List A, Verma A. High Resolution Epigenomic Profiling of Loss of Heterozygosity in MDS Reveals an Important Role of DNA Methylation in Regulating Expression of Genes in the Deleted Regions of Chromosomes 5q, 7q and 20q. Blood. 110: 2120-2120. DOI: 10.1182/Blood.V110.11.2120.2120 | 0.425 | |||
| 2007 | Figueroa ME, Wouters BJ, Li Y, Valk P, Lowenberg B, Melnick AM, Delwel R. Genetic vs. Epigenetic Disruption of the CEBPA Locus Yields Epigenomically and Biologically Distinct Leukemia Phenotypes. Blood. 110: 2117-2117. DOI: 10.1182/BLOOD.V110.11.2117.2117 | 0.339 | |||
| 2007 | Velichutina I, Melnick A. Regulation of Hox Genes by Polycomb Group Protein EZH2 Plays a Critical Role in Diffuse Large B-Cell Lymphoma Cells. Blood. 110: 1562-1562. DOI: 10.1182/Blood.V110.11.1562.1562 | 0.524 | |||
| 2007 | Opalinska J, Sohal D, Thompson R, Zhou L, Li Y, Pahanish P, Kotla V, Kambhampati S, Parmar S, Friedman E, Figueroa M, Ye K, Wickrema A, Melnick A, Greally J, et al. Global DNA Methylation Profiling Demonstrates That Idiopathic Myelofibrosis Is Characterized by a Distinct Epigenetic Signature with Aberrant Methylation Changes in Genes Involved in Inflammation and Hematopoiesis Blood. 110: 1536-1536. DOI: 10.1182/Blood.V110.11.1536.1536 | 0.424 | |||
| 2006 | Khulan B, Thompson RF, Ye K, Fazzari MJ, Suzuki M, Stasiek E, Figueroa ME, Glass JL, Chen Q, Montagna C, Hatchwell E, Selzer RR, Richmond TA, Green RD, Melnick A, et al. Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Research. 16: 1046-55. PMID 16809668 DOI: 10.1101/Gr.5273806 | 0.343 | |||
| 2006 | Privé GG, Melnick A. Specific peptides for the therapeutic targeting of oncogenes. Current Opinion in Genetics & Development. 16: 71-7. PMID 16377176 DOI: 10.1016/J.Gde.2005.12.010 | 0.327 | |||
| 2006 | Prokhortchouk A, Sansom O, Selfridge J, Caballero IM, Salozhin S, Aithozhina D, Cerchietti L, Meng FG, Augenlicht LH, Mariadason JM, Hendrich B, Melnick A, Prokhortchouk E, Clarke A, Bird A. Kaiso-deficient mice show resistance to intestinal cancer. Molecular and Cellular Biology. 26: 199-208. PMID 16354691 DOI: 10.1128/Mcb.26.1.199-208.2006 | 0.369 | |||
| 2006 | Ryan M, Cerchietti L, Figueroa ME, Greally J, Melnick A. Sensitivity of Diffuse Large B-Cell Lymphomas to DNA Methyltransferase Inhibitors Is Associated with a Specific Epigenetic Signature. Blood. 108: 831-831. DOI: 10.1182/Blood.V108.11.831.831 | 0.464 | |||
| 2006 | Antun A, Cerchietti L, Aparo S, Shaknovich R, Melnick A. BCL6 Inhibitor Peptide Have Powerful Anti-Lymphoma Activity in Animal Models of Diffuse Large B-Cell Lymphoma and Synergize with Other Anti-Lymphoma Drugs. Blood. 108: 827-827. DOI: 10.1182/Blood.V108.11.827.827 | 0.442 | |||
| 2006 | Figueroa ME, Ye K, Paietta E, Greally JM, Melnick AM. Epigenetic Signatures Accurately Distinguish Leukemia Subtypes and Provide a More Comprehensive Representation of Differentially Regulated Genes Than Gene Expression Profiling. Blood. 108: 735-735. DOI: 10.1182/Blood.V108.11.735.735 | 0.337 | |||
| 2006 | Polo JM, Juszczynski P, Cerchietti L, Monti S, Ye K, Shipp MA, Melnick AM. A BCL6 Target Gene Signature Predicts the Biological Behavior and Classification of Diffuse Large B-Cell Lymphoma. Blood. 108: 616-616. DOI: 10.1182/Blood.V108.11.616.616 | 0.406 | |||
| 2006 | Sohal D, Yeatts A, Opalinska J, Zhou L, Pahanish P, Ye K, Figueroa M, Mariadason J, Melnick A, Greally J, Verma A. Meta-Transcriptome of Bone Marrow Stem Cells Demonstrates Platform and Lab Dependant Variability in Gene Expression and Reveals a Novel Set of Enriched Genes. Blood. 108: 4189-4189. DOI: 10.1182/Blood.V108.11.4189.4189 | 0.402 | |||
| 2006 | Opalinska J, Sohal D, Parmar S, Zhou L, Yeatts A, Pahanish P, Isulfi I, Ye K, Figueroa M, Melnick A, Greally J, Verma A. A High Resolution Epigenomic Map of Myelofibrosis Reveals Multiple Chromosomal Deletions and Amplifications Accompanied by a High Level of Functionally Important Methylation. Blood. 108: 2684-2684. DOI: 10.1182/Blood.V108.11.2684.2684 | 0.412 | |||
| 2006 | Zhou L, Opalinska J, Sohal D, Parmar S, Pahanish P, Isulfi I, Ye K, Figueroa M, Greally J, Melnick A, Verma A. High Resolution Epigenomic Mapping of Myelodysplastic Syndrome Reveals a High Level of Functionally Important Methylation. Blood. 108: 2637-2637. DOI: 10.1182/Blood.V108.11.2637.2637 | 0.418 | |||
| 2006 | Parekh S, Polo J, Juszczynski P, Lev P, Ranuncolo S, Cattoretti G, Shaknovich R, Shipp M, Melnick A. BCL6 Programs Lymphoma Cells for Survival and Differentiation through Distinct Biochemical Mechanisms, Both of Which Can Be Therapeutically Targeted. Blood. 108: 225-225. DOI: 10.1182/Blood.V108.11.225.225 | 0.499 | |||
| 2006 | Ranuncolo SM, Polo JM, Dierov J, Carroll M, Melnick AM. A Critical BCL6-Related Feedback Loop Explains the Unusual Biological Features of Germinal Center B-Cells and Their Malignant Transformation into B-Cell Lymphomas. Blood. 108: 224-224. DOI: 10.1182/BLOOD.V108.11.224.224 | 0.362 | |||
| 2006 | Cerchietti L, Figueroa ME, Shaknovich R, Melnick A. BCL6 Regulates Diffuse Large B-Cell Lymphoma Cell Cycle and Apoptosis Checkpoints through Direct Repression of the p300 Histone Acetyl-Transferase. Blood. 108: 1413-1413. DOI: 10.1182/Blood.V108.11.1413.1413 | 0.422 | |||
| 2006 | Rice KL, Melnick A, Ye K, Berkofsky-Fessler W, Licht JD. A Comprehensive Genomic Approach Using Gain of Function and Loss of Function Cell Models and ChIP-on-Chip Technology Identifies Novel Promyelocytic Zinc Finger Protein Target Genes. Blood. 108: 1407-1407. DOI: 10.1182/Blood.V108.11.1407.1407 | 0.621 | |||
| 2005 | Melnick AM, Adelson K, Licht JD. The theoretical basis of transcriptional therapy of cancer: can it be put into practice? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3957-70. PMID 15867201 DOI: 10.1200/JCO.2005.14.498 | 0.571 | |||
| 2005 | Melnick A. Predicting the effect of transcription therapy in hematologic malignancies. Leukemia. 19: 1109-1117. PMID 15858614 DOI: 10.1038/Sj.Leu.2403777 | 0.414 | |||
| 2005 | Melnick A. Reprogramming specific gene expression pathways in B-cell lymphomas. Cell Cycle (Georgetown, Tex.). 4: 239-41. PMID 15655367 | 0.422 | |||
| 2005 | Melnick A. Reprogramming specific gene expression pathways in B-cell lymphomas. Cell Cycle. 4: 239-241. DOI: 10.4161/Cc.4.2.1469 | 0.505 | |||
| 2005 | Polo JM, Ranuncolo SM, Parek S, Arcaya J, Melnick AM. The BCL6 Oncoprotein Forms Distinct Transcriptional Repression Complexes on Cohorts of Target Genes Involved in Specific Cellular Functions. Blood. 106: 2615-2615. DOI: 10.1182/BLOOD.V106.11.2615.2615 | 0.422 | |||
| 2005 | Ranuncolo SM, Polo JM, Dierov J, Shaknovich R, Carroll M, Melnick AM. BCL6 Attenuates DNA Damage Sensing in Normal and Malignant B-Cells by Directly Repressing ATR. Blood. 106: 157-157. DOI: 10.1182/BLOOD.V106.11.157.157 | 0.367 | |||
| 2005 | Cerchietti LC, Polo JM, Da Silva GF, Dowdy SM, Giorgio CM, Rita SM, Melnick AM. BCL6, p53 and Molecular Targeted Therapy in B-Cell Lymphomas. Blood. 106: 1484-1484. DOI: 10.1182/BLOOD.V106.11.1484.1484 | 0.302 | |||
| 2004 | Polo JM, Dell'Oso T, Ranuncolo SM, Cerchietti L, Beck D, Da Silva GF, Prive GG, Licht JD, Melnick A. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nature Medicine. 10: 1329-35. PMID 15531890 DOI: 10.1038/Nm1134 | 0.623 | |||
| 2004 | Takahashi S, McConnell MJ, Harigae H, Kaku M, Sasaki T, Melnick AM, Licht JD. The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT. Blood. 103: 4650-8. PMID 14982881 DOI: 10.1182/blood-2003-08-2759 | 0.552 | |||
| 2004 | Chevallier N, Corcoran CM, Lennon C, Hyjek E, Chadburn A, Bardwell VJ, Licht JD, Melnick A. ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein. Blood. 103: 1454-63. PMID 14551142 DOI: 10.1182/Blood-2003-06-2081 | 0.658 | |||
| 2004 | Polo JM, Dell’Oso T, Ranuncolo SM, Cerchietti L, Silva GFD, Prive GG, Licht JD, Melnick A. Specific Peptide Disruption of the Bcl-6 Repression Complex Reveals Its Transcriptional Mechanism of Action in Normal and Malignant B-Cells and Is a Novel Therapeutic Approach for Diffuse Large B-Cell Lymphoma. Blood. 104: 5-5. DOI: 10.1182/Blood.V104.11.5.5 | 0.668 | |||
| 2003 | Ahmad KF, Melnick A, Lax S, Bouchard D, Liu J, Kiang CL, Mayer S, Takahashi S, Licht JD, Privé GG. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Molecular Cell. 12: 1551-64. PMID 14690607 DOI: 10.1016/S1097-2765(03)00454-4 | 0.602 | |||
| 2003 | Sirulnik A, Melnick A, Zelent A, Licht JD. Molecular pathogenesis of acute promyelocytic leukaemia and APL variants. Best Practice & Research. Clinical Haematology. 16: 387-408. PMID 12935958 DOI: 10.1016/S1521-6926(03)00062-8 | 0.588 | |||
| 2002 | Melnick A, Licht JD. Histone deacetylases as therapeutic targets in hematologic malignancies. Current Opinion in Hematology. 9: 322-32. PMID 12042707 DOI: 10.1097/00062752-200207000-00010 | 0.627 | |||
| 2002 | Melnick A, Carlile G, Ahmad KF, Kiang CL, Corcoran C, Bardwell V, Prive GG, Licht JD. Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors. Molecular and Cellular Biology. 22: 1804-18. PMID 11865059 DOI: 10.1128/Mcb.22.6.1804-1818.2002 | 0.567 | |||
| 2001 | Zelent A, Guidez F, Melnick A, Waxman S, Licht JD. Translocations of the RARalpha gene in acute promyelocytic leukemia. Oncogene. 20: 7186-7203. PMID 11704847 DOI: 10.1038/Sj.Onc.1204766 | 0.593 | |||
| 2000 | Melnick A, Carlile GW, McConnell MJ, Polinger A, Hiebert SW, Licht JD. AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein. Blood. 96: 3939-47. PMID 11090081 DOI: 10.1182/Blood.V96.12.3939.H8003939_3939_3947 | 0.619 | |||
| 2000 | Melnick A, Ahmad KF, Arai S, Polinger A, Ball H, Borden KL, Carlile GW, Prive GG, Licht JD. In-depth mutational analysis of the promyelocytic leukemia zinc finger BTB/POZ domain reveals motifs and residues required for biological and transcriptional functions. Molecular and Cellular Biology. 20: 6550-67. PMID 10938130 DOI: 10.1128/Mcb.20.17.6550-6567.2000 | 0.542 | |||
| 2000 | Melnick AM, Westendorf JJ, Polinger A, Carlile GW, Arai S, Ball HJ, Lutterbach B, Hiebert SW, Licht JD. The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein Molecular and Cellular Biology. 20: 2075-2086. PMID 10688654 DOI: 10.1128/Mcb.20.6.2075-2086.2000 | 0.536 | |||
| 2000 | Melnick A, Westendorf J, Polinger A, Carlile G, Arai S, Ball H, Lutterbach B, Hiebert S, Licht J. Interaction between plzf and eto-a possible link in the molecular mechanisms of M2 and M3 leukemia Experimental Hematology. 28: 129-130. DOI: 10.1016/S0301-472X(00)00500-2 | 0.604 | |||
| 1999 | Melnick A, Fruchtman S, Zelent A, Liu M, Huang Q, Boczkowska B, Calasanz MJ, Fernandez A, Licht JD, Najfeld V. Identification of novel chromosomal rearrangements in acute myelogenous leukemia involving loci on chromosome 2p23, 15q22 and 17q21 Leukemia. 13: 1534-1538. PMID 10516754 DOI: 10.1038/Sj.Leu.2401513 | 0.525 | |||
| 1999 | Ball HJ, Melnick A, Shaknovich R, Kohanski RA, Licht JD. The promyelocytic leukemia zinc finger (PLZF) protein binds DNA in a high molecular weight complex associated with cdc2 kinase Nucleic Acids Research. 27: 4106-4113. PMID 10497277 DOI: 10.1093/Nar/27.20.4106 | 0.567 | |||
| 1999 | Hoatlin ME, Zhi Y, Ball H, Silvey K, Melnick A, Stone S, Arai S, Hawe N, Owen G, Zelent A, Licht JD. A novel BTB/POZ transcriptional repressor protein interacts with the Fanconi anemia group C protein and PLZF. Blood. 94: 3737-3747. DOI: 10.1182/Blood.V94.11.3737.423K39_3737_3747 | 0.579 | |||
| 1999 | Hoatlin ME, Zhi Y, Ball H, Silvey K, Melnick A, Stone S, Arai S, Hawe N, Owen G, Zelent A, Licht JD. A Novel BTB/POZ Transcriptional Repressor Protein Interacts With the Fanconi Anemia Group C Protein and PLZF Blood. 94: 3737-3747. DOI: 10.1182/blood.v94.11.3737 | 0.527 | |||
| 1999 | Melnick A, Licht JD. Deconstructing a Disease: RAR, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia Blood. 93: 3167-3215. DOI: 10.1182/Blood.V93.10.3167.410K44_3167_3215 | 0.506 | |||
| 1998 | Shaknovich R, Yeyati PL, Ivins S, Melnick A, Lempert C, Waxman S, Zelent AZ, Licht JD. The Promyelocytic Leukemia Zinc Finger Protein Affects Myeloid Cell Growth, Differentiation, and Apoptosis Molecular and Cellular Biology. 18: 5533-5545. PMID 9710637 DOI: 10.1128/Mcb.18.9.5533 | 0.609 | |||
| Show low-probability matches. | |||||